Page last updated: 2024-11-04

antipyrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2206
CHEMBL ID277474
CHEBI ID31225
SCHEMBL ID20452
MeSH IDM0001499

Synonyms (203)

Synonym
MLS001331753
MLS002154179
smr000238140
1,5-dimethyl-2-phenyl-2,3-dihydro-1h-pyrazol-3-one
BRD-K46937689-001-05-1
3-antipyrine
nsc-7945
phenozone
azophen
phenylone
analgesine
1-phenyl-2,3-dimethylpyrazole-5-one
2,3-dimethyl-1-phenyl-3-pyrazolin-5-one
1-phenyl-2,3-dimethyl-5-pyrazolone
apirelina
.beta.-antipyrine
anodynin
pyrazophyl
phenazonum
phenazone (pharmaceutical)
2,3-dimethyl-1-phenyl-5-pyrazolone
phenazone
antipyrin
anodynine
component of auralgan
oxydimethylquinazine
antipirin
dimethyloxychinizin
methozin
dimethyloxyquinazine
phenazon
sedatin
antipyrine
sedatine
nsc7945
phenylon
wln: t5nnvj a1 br& e1
azophene
60-80-0
oxydimethylquinizine
parodyne
fenazone
3h-pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-
DIVK1C_000484
KBIO1_000484
fenazona
CHEBI:31225 ,
1,2-dihydro-1,5-dimethyl-2-phenyl-3h-pyrazol-3-one
1,5-dimethyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one
fenazon [czech]
phenazonum [inn-latin]
ai3-15293
ccris 1369
azophenum
antipyrine [jan]
fenazona [inn-spanish]
nsc 7945
antipyrinum
einecs 200-486-6
SPECTRUM_000058
PRESTWICK_26
cas-60-80-0
NCGC00016274-01
BSPBIO_001870
BSPBIO_000097
PRESTWICK2_000029
NCGC00178937-02
NCGC00178937-01
1,5-dimethyl-2-phenyl-pyrazol-3-one
IDI1_000484
SPECTRUM5_000842
BPBIO1_000107
MLS001332402
MLS001332401
BIM-0051287.0001
antipyrine, analytical standard
DB01435
phenazone (inn)
D01776
antipyrine (jp17/usp)
NCGC00094591-02
NCGC00094591-01
NCGC00094591-03
KBIO2_000438
KBIOSS_000438
KBIO2_003006
KBIOGR_000624
KBIO2_005574
KBIO3_001370
SPBIO_002018
SPBIO_000016
SPECTRUM2_000088
SPECTRUM4_000152
PRESTWICK1_000029
PRESTWICK0_000029
SPECTRUM3_000305
NINDS_000484
SPECTRUM1500128
PRESTWICK3_000029
STK328171
HMS2091K09
CHEMBL277474
AKOS000588788
HMS501I06
FT-0662246
D1876
HMS1920E09
HMS1568E19
1,5-dimethyl-2-phenylpyrazol-3-one
NCGC00016274-04
1,2-dihydro-1,5-dimethyl-2-phenyl-3h-pyrazol-3-one; phenazone
A19580
HMS2095E19
dtxsid6021117 ,
NCGC00256527-01
tox21_303026
dtxcid401117
AF-960/00437050
tox21_201600
NCGC00259149-01
nsc-755874
pharmakon1600-01500128
nsc755874
tox21_110342
HMS2272G04
S3173
CCG-38904
NCGC00016274-03
NCGC00016274-06
NCGC00016274-05
NCGC00016274-07
NCGC00016274-02
antipyrine [usp:jan]
ec 200-486-6
t3cha1b51h ,
fenazon
phenazone [inn]
unii-t3cha1b51h
2-trideuteromethyl-3-methyl-1-phenyl-3-pyrazolin-5-one
FT-0609690
antipyrine [usp-rs]
phenazone [mart.]
phenazone [ep impurity]
antipyrine [usp monograph]
antipyrine [mi]
phenazone [who-dd]
antipyrine [vandf]
phenazone [ep monograph]
antipyrine [usp impurity]
propyphenazone impurity a [ep impurity]
antipyrinum [hpus]
EPITOPE ID:124927
HY-B0171
CS-2044
SCHEMBL20452
tox21_110342_1
NCGC00016274-10
F2173-0728
Q-201552
1,5-dimethyl-2-phenyl-3-pyrazolone
1,5-dimethyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one #
antipyrine, sigma reference standard
antipyrine, analytical reference material
mfcd00003146
antipyrine, >=99.0% (rt)
antipyrine, united states pharmacopeia (usp) reference standard
antipyrine, tested according to ph.eur.
HMS3652C09
SR-05000001566-3
SR-05000001566-1
sr-05000001566
bdbm50103600
phenazone, european pharmacopoeia (ep) reference standard
antipyrine, vetec(tm) reagent grade, 98%
Z56869297
SBI-0051287.P003
HMS3712E19
SW196343-3
1,5-dimethyl-2-phenyl-1h-pyrazol-3(2h)-one
Q415578
AS-13248
BRD-K46937689-001-08-5
HMS3885C11
phenazone;phenazon
H11233
antipyrien
A936893
NCGC00016274-09
phenazone 10 microg/ml in acetonitrile
EN300-17057
1,5-dimethyl-2-phenyl-1,2-dihydropyrazol-3-one
phenazone (ep monograph)
propyphenazone impurity a (ep impurity)
antipyrine (usp impurity)
antipyrine (usp:jan)
antipyrine (usp-rs)
fenazona (inn-spanish)
phenazonum (inn-latin)
s02da03
phenazone (ep impurity)
antipyrine (usp monograph)
phenazone (mart.)
n02bb01

Research Excerpts

Overview

Antipyrine is a "gold standard" measure of mixed cytochrome P450 (CYP) mediated drug metabolism in humans. It is used to evaluate variation of in vivo activities of oxidative hepatic drug-metabolizing enzymes.

ExcerptReferenceRelevance
"Antipyrine metabolism is a "gold standard" measure of mixed cytochrome P450 (CYP) mediated drug metabolism in humans. "( Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.
Burckart, GJ; Carcillo, JA; Doughty, L; Frye, RF; Kaplan, SS; Kofos, D; Sasser, H, 2003
)
1.76
"Antipyrine is a marker of hepatic oxidative function and total body water."( Antipyrine pharmacokinetics in the tail-suspended rat model.
Brunner, LJ; DiPiro, JT; Feldman, S, 1995
)
2.46
"Antipyrine is a marker of hepatic oxidative function and total body water."( Metabolic cage isolation reduces antipyrine clearance in rats.
Brunner, LJ; Dipiro, JT; Feldman, S, 1994
)
1.29
"Antipyrine is a useful probe to evaluate variation of in vivo activities of oxidative hepatic drug-metabolizing enzymes. "( Direct detection of antipyrine metabolites in rat urine by (13)C labeling and NMR spectroscopy.
Akira, K; Hashimoto, T; Negishi, E; Sakuma, C, 1999
)
2.07
"Antipyrine is a useful probe to evaluate variation of in vivo activities of oxidative hepatic drug-metabolizing enzymes. "( Direct nuclear magnetic resonance spectroscopic analysis of (13)C-labeled antipyrine metabolites in human urine.
Akira, K; Hashimoto, T; Imachi, M; Negishi, E, 2001
)
1.98
"Antipyrine (AP) serves as a model drug for drugs which are eliminated independently of liver blood flow and lorcainide (L) elimination as a model for drugs which depend on liver blood flow."( Alterations in the disposition of differently cleared drugs in patients with cirrhosis.
Fischer, C; Klotz, U; Müller, WA; Müller-Seydlitz, P; Schulz, J, 1979
)
0.98
"Antipyrine is a pharmacokinetic model substance to estimate the cytochrome P 450 enzyme activity."( Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections.
Brockmeyer, NH; Goos, M; Mertins, L; Spatz, D; Tillmann, I, 1992
)
1.27
"Antipyrine (AP) is a commonly used probe of oxidative metabolism. "( The pharmacokinetics of antipyrine and three of its metabolites in the rabbit: intravenous administration of pure metabolites.
Abul-Hajj, Y; Awni, WM; St Peter, JV, 1991
)
2.03
"Antipyrine is a useful marker drug for cytochrome P-450 dependent hepatic drug metabolism."( Hepatic drug metabolism is increased in poorly controlled insulin-dependent diabetes mellitus.
Goldstein, S; Saenger, P; Simpson, A, 1990
)
1
"Antipyrine is a pyrazole derivative used extensively as a marker for hepatic drug metabolizing enzyme activity. "( Allergic reaction to antipyrine, a marker of hepatic enzyme activity.
McCrea, JB; Rocci, ML; Vlasses, PH, 1989
)
2.04
"The antipyrine half-life is a reliable index of biotransformation capacity of the liver. "( [The antipyrine test in occupational medicine research--evaluation of individual reproducibility and frequency distribution of half-life].
Damrau, J; Skölziger, R; Uhlig, H, 1989
)
1.35
"As antipyrine is a low extraction drug and is not bound to serum proteins, the decreased systemic clearance suggests a lower hepatic intrinsic clearance, and this was again confirmed by a decreased metabolizing activity in the isolated hepatocytes."( Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat.
Belpaire, FM; Bogaert, MG; Chindavijak, B; De Smet, F, 1988
)
1.02

Effects

Antipyrine clearance has been measured from serial saliva samples in 36 healthy adult Indo-Pakistani immigrants to Britain, to assess the effect of dietary differences within this population. 131I-antipYRine has a more convenient pulmonary interstitial oedema.

ExcerptReferenceRelevance
"131I-antipyrine has a more convenient pulmonary interstitial oedema."( [Estimation of lung water with 131I-antipyrine and 99mTc-HSA (author's transl)].
Falkensammer, M; Noelpp, U; Rösler, H, 1979
)
0.99
"1 Antipyrine clearance has been measured from serial saliva samples in 36 healthy adult Indo-Pakistani immigrants to Britain, to assess the effect of dietary differences within this population. "( The relationship between individual dietary constituents and antipyrine metabolism in Indo-Pakistani immigrants to Britain.
Caraher, MT; Chapman, PH; Henderson, DB; Mucklow, JC; Rawlins, MD; Roberts, DF, 1982
)
1.23
"1 Antipyrine clearance has been measured using saliva samples in 50 Maharashtrans from a village to the north of Bombay. "( Antipyrene clearance in Indian villagers.
Bulpitt, CJ; Desai, NK; Dollery, CT; Fraser, HS; Jones, SW; Mucklow, JC; Sheth, UK, 1980
)
0.98
"Antipyrine has been used extensively in fetal metabolic studies and is now known to inhibit prostaglandin synthesis; therefore we wished to determine the effects of antipyrine on fetal umbilical and regional metabolism."( Effects of antipyrine on umbilical and regional metabolism in late gestation in the fetal lamb.
Charlton, V; Gull, I, 1993
)
2.12
"Antipyrine has been widely used as a probe drug for human oxidative drug metabolism. "( Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Cosme, J; Eichelbaum, M; Engel, G; Heidemann, H; Hofmann, U, 1996
)
3.18
"Antipyrine has particular pharmacological properties, and its plasma clearance represents quantitatively the functional capacity of the liver."( Estimation of functional liver reserve in patients before cardiac surgery using antipyrine plasma clearance test.
Furuse, A; Kawauchi, M; Kotsuka, Y; Takamoto, S; Takeda, M, 1999
)
1.25
"131I-antipyrine has a more convenient pulmonary interstitial oedema."( [Estimation of lung water with 131I-antipyrine and 99mTc-HSA (author's transl)].
Falkensammer, M; Noelpp, U; Rösler, H, 1979
)
0.99
"Antipyrine has been used previously to estimate total body water in infants. "( Serial measurements of plasma half-lives and urinary excretion of antipyrine in low-birth-weight infants.
Davies, DS; Murdock, AI; Rossiger, H; Thorgeirsson, SS, 1975
)
1.93
"Antipyrine disposition has been determined in the rat following administration of Fluosol-DA by an intravenous infusion without blood removal or a haemodilution procedure, and compared with data from sham haemodiluted rats (blood removed and returned) and control rats which only received antipyrine. "( Influence of the method of fluosol-DA administration on antipyrine metabolism in the rat.
Shrewsbury, RP; White, LG, 1990
)
1.97
"Antipyrine half-life has been determined from measurements of antipyrine concentrations in spontaneously voided urine specimens in eleven subjects, studied on a total of forty-seven different occasions while receiving no drugs, interferon or ketoconazole. "( Plasma antipyrine half-life can be determined from urine data.
Atiba, JO; Blaschke, TF; Pershe, RA; Taylor, G, 1987
)
2.17
"The antipyrine (AP) test has been challenged in species other than humans on the grounds that, in some nonhuman species, particularly on induction, hepatic blood flow may become as prominent a factor in AP clearance as hepatic metabolism. "( On the antipyrine test in laboratory animals. Studies in the dog and monkey.
Bowman, TA; Dvorchik, BH; Hughes, DM; Passananti, GT; Vesell, ES; Vickers, FF,
)
1.14
"Antipyrine has recently been shown to decrease prostaglandin production in mature fetuses. "( Effects of antipyrine on electrocortical state and regional blood flows in the mature sheep fetus.
Neaves, N; Phernetton, TM; Rankin, JH; Reid, DL; Slotten, P, 1989
)
2.11
"Antipyrine kinetics has therefore been determined in 12 patients on the fourth day following tetanus vaccination."( Antipyrine kinetics following tetanus vaccination.
Descotes, J; Evreux, JC; Simonet, R, 1986
)
2.44
"Antipyrine clearance has been measured from serial serum samples in 49 healthy black Africans from a village in Southern Africa. "( Antipyrine metabolism in African villagers.
Moncrieff, J; Schoeman, HS; Sommers, DK; van Staden, DA, 1985
)
3.15
"Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. "( Determinants of serum antipyrine half-lives in patients with liver disease.
Branch, RA; Herbert, CM; Read, AE, 1973
)
2.01

Treatment

ExcerptReferenceRelevance
"3 Antipyrine treatment produced a fall in circulating 25-hydroxyvitamin D of around 60% in all subjects in whom pretreatment levels could be measured, independent of race and diet."( Reduction of circulating 25-hydroxyvitamin D by antipyrine.
Brodie, MJ; Davies, DS; Dollery, CT; Fraser, HS; Hillyard, CJ; Macintyre, I; Mucklow, JC; Park, BK; Toverud, EL; Wilmana, PF, 1979
)
1.07

Toxicity

ExcerptReferenceRelevance
" Three patients (one on ketorolac, two on Doleron) withdrew because of adverse events (vomiting)."( Analgesic efficacy and safety comparison of ketorolac tromethamine and Doleron for the alleviation of orthopaedic post-operative pain.
Johansson, S; Josefsson, G; Lindstrand, A; Malstam, J; Stenstroem, A,
)
0.13
" In an animal model used to assess the effect of cimetidine on acetaminophen toxicity, the LD50 of acetaminophen alone in Charles River CD-1 mice was 480 mg/kg (95% confidence interval: 436-528 mg/kg)."( Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine.
Abernethy, DR; Ameer, B; Divoll, M; Greenblatt, DJ; Shader, RI, 1983
)
0.52
" In LD50 parameters it was found to be related to moderately toxic drugs."( [A preclinical trial of iodoantipyrine safety].
Akhmedzhanov, RR; Bashirova, LV; Burchenkova, FI; Eremina, AA; Kadychagova, NG; Livshits, NS; Novozheeva, TP; Potapova, GV; Saratikov, AS,
)
0.43
"Controlled oral challenge with nonsteroidal anti-inflammatory drugs (NSAIDs) is the only definite way to detect safe NSAIDs in patients with NSAID-induced anaphylactoid reactions."( Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
Conde, J; Delgado, J; Florido, JF; López-Pascual, E; Nieto, MA; Ortega, N; Quiralte, J; Sáenz de San Pedro, B, 2004
)
0.32
"The SBPCOCs with highly selective COX-2 inhibitors were safe in patients with single-reactive, NSAID-induced anaphylactoid reactions, even in cases that involved pyrazole derivatives."( Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
Conde, J; Delgado, J; Florido, JF; López-Pascual, E; Nieto, MA; Ortega, N; Quiralte, J; Sáenz de San Pedro, B, 2004
)
0.32
" No adverse events were observed."( Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger.
Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012
)
0.38
"Edaravone was safe and well tolerated in the volunteers and displayed linear increases in the C(max) and AUC(τ) values."( Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions.
Gong, X; Li, H; Li, T; Meng, L; Ou, N; Ruan, J; Wang, Y; Xu, K; Zhang, H, 2012
)
0.38
" Edaravone effectively protected against CNS-OT and the adverse effects of PFC."( Perfluorocarbon-facilitated CNS oxygen toxicity in rats: reversal by edaravone.
Cai, Z; Li, R; Liu, S; Ni, X; Quock, RM; Sun, X; Xu, W; Zhang, R, 2012
)
0.38
" Safety parameters included adverse events, severe adverse events, physical examinations, local reactions at infusion site, ECG, clinical chemistry and hematology, modified Total Neuropathy Score and CT scans."( Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Dippel, DW; Ford, GA; Kaste, M; Murayama, S; Tatlisumak, T; Walters, MR, 2013
)
0.39
" The number of treatment emergent adverse events that occurred was 109, most of which were transient, mild or moderate."( Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Dippel, DW; Ford, GA; Kaste, M; Murayama, S; Tatlisumak, T; Walters, MR, 2013
)
0.39
" Adverse events amounted to 88."( Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Abe, K; Akimoto, M; Aoki, M; Doyu, M; Hamada, C; Itoyama, Y; Kondo, K; Sobue, G; Tsuji, S; Yoneoka, T; Yoshino, H, 2014
)
0.4
" Previous studies have reported an increased generation of reactive oxygen species and oxidative stress in the toxic mechanism of VPA."( Edaravone ameliorates the adverse effects of valproic acid toxicity in small intestine.
Alev, B; Emekli-Alturfan, E; Koc-Ozturk, L; Oktay, S; Tunali, S; Tunali-Akbay, T; Yanardag, R; Yarat, A, 2015
)
0.42
"A dose-dependent toxic effect of Auralgan was noted on cultured cells."( Assessment of ototoxicity of intratympanic administration of Auralgan in a chinchilla animal model.
Bezdjian, A; Daniel, SJ; Mujica-Mota, MA; Salehi, P; Schermbrucker, J, 2015
)
0.42
" The aim of the present study was to assess the toxic effects of subacute exposure of Mn by measuring weight gain, motor performance, and biochemical parameters (complex I activity, lipid peroxides, and protein carbonyls) in brain mitochondria in rats."( Protection by Edaravone, a Radical Scavenger, against Manganese-Induced Neurotoxicity in Rats.
Apaydin, M; Erbas, O; Taskiran, D, 2016
)
0.43
" Treatment-emergent adverse events were reported in 58 (84%) patients receiving edaravone and 57 (84%) patients receiving placebo."( Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
, 2017
)
0.46
" Endpoints included treatment-emergent adverse events (TEAEs), including AEs leading to discontinuation, serious adverse events (SAEs), and deaths."( A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
Ishizaki, K; Kalin, A; Kim, A; Medina-Paraiso, E; Saita, T; Wasaki, M; Zhang, Y, 2017
)
0.46
" Conclusively, blood system (especially erythrocyte system) and digestive system, including liver and gastrointestinal tract, might be the toxic targets of ALED."( Preclinical safety assessment of antipyrine combined with lidocaine hydrochloride as ear drops.
Ba, JB; Chu, ZY; Feng, X; Liu, WH; Zhang, XD; Zou, YX, 2019
)
0.8
" In a previous study, we have shown that N-methyl-4-aminoantipyrine (MAA), the active metamizole metabolite, reacts with hemin and forms an electrophilic metabolite that is toxic for HL60 cells, but not for mature neutrophil granulocytes."( Toxicity of metamizole on differentiating HL60 cells and human neutrophil granulocytes.
Duthaler, U; Krähenbühl, S; Roos, NJ; Rudin, D, 2019
)
0.76
" Safety endpoints was include the incidence of adverse drug reactions."( Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
Gupta, S; Singal, A; Soni, R; Tomar, S, 2022
)
0.72
"6%) of subjects receiving Edaravone therapy reported with adverse side-effects."( Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
Gupta, S; Singal, A; Soni, R; Tomar, S, 2022
)
0.72

Pharmacokinetics

Paracetamol (PA) and antipyrine (AP) were studied in pigs to investigate the usefulness of this combination for the simultaneous assessment of oxidative and conjugative metabolism. Discriminant analysis of the basal data revealed that plasma bilirubin, proteins and antipYRine half-life taken together had a strong association with mortality.

ExcerptReferenceRelevance
" From these observations it is concluded that a specific pharmacokinetic behaviour of acidic NSAID leading to high concentrations in inflamed tissue is a decisive aspect of their anti-inflammatory action."( Inhibition of prostaglandin synthesis in vivo by nonsteroid anti-inflammatory drugs: evidence for the importance of pharmacokinetics.
Brune, K; Glatt, M; Graf, P, 1976
)
0.26
" After 3 mo of oral steroid therapy (Norinyl, 2 mg; norethindrone + mestranol), the antipyrine half-life was increased in 3 of 6 subjects, phenylbutazone half-life was not consistently altered, and vitamin D3 half-life was increased in 3 of 4 patients."( Effect of oral contraceptives on plasma clearance.
Bressler, R; Carter, DE; Christian, D; Haussler, MR; Heine, MW; Hughes, MR, 1975
)
0.48
" The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3."( Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver.
Andreasen, PB; Hutters, L, 1979
)
0.26
"Plasma half-life and metabolic clearance rate of antipyrine administered intravenously in a dose of 16 mg/kg body weight was studied in 10 children suffering from protein calorie malnutrition and five normal children matched in age and sex."( Pharmacokinetic study of antipyrine in malnourished children.
Mathur, VS; Mehta, S; Narang, RK, 1977
)
0.81
"Studies were carried out on the pharmacokinetic behaviour of 5-oxo-2,3-dimethyl-1-phenyl-3-pyrazoline (phenazone) by means of intraindividual comparison following oral and rectal administration in man."( [On the pharmacokinetics of phenazone in man (author's transl)].
Brinkmann, HJ; Hengstmann, JH; Müller, F, 1977
)
0.26
" Pharmacokinetic analysis of antipyrine from saliva utilizing a simple and sensitive colourimetric technique provided a convenient method for assessing the activity of hepatic microsomal drug-metabolizing enzymes."( A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis.
Frewin, DB; Harman, AE; Priestly, BG,
)
0.73
" Antipyrine elimination half-life (t1/2), volume of distribution (Vd), and total clearance were determined after each trial."( Impairment of antipyrine clearance in humans by propranolol.
Franke, K; Greenblatt, DJ; Huffman, DH, 1978
)
1.53
" Estimates of clearance, volume of distribution, and half-life made from either plasma or saliva samples were not statistically different in these subjects."( Application of salivary concentration data to pharmacokinetic studies with antipyrine.
Blaschke, TF; Meffin, PJ; Rowland, M; Williams, RL, 1977
)
0.49
"The plasma half-life and metabolic clearance rate of antipyrine, a drug metabolized by hepatic microsomal enzymes, were determined in 33 normal volunteers during a basal state and during fever induced with a single intramuscular injection of etiocholanolone."( Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.
Elin, RJ; Vesell, ES; Wolff, SM, 1975
)
0.76
" No significant differences were seen in the pharmacokinetic parameters observed for antipyrine, a drug which is less than 10% bound to plasms proteins."( Pharmacokinetics of drugs in patients with the nephrotic syndrome.
Azarnoff, DL; Cohlmia, JB; Gugler, R; Huffman, DH; Shoeman, DW, 1975
)
0.48
" Antipyrine is a pharmacokinetic model substance to estimate the cytochrome P 450 enzyme activity."( Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections.
Brockmeyer, NH; Goos, M; Mertins, L; Spatz, D; Tillmann, I, 1992
)
1.46
" Pharmacokinetic assays were performed in all animals: prior to the study, after 1 month and after 2 months."( [Pharmacokinetics of phenazone after bilateral ovariectomy in female rabbits].
Droździk, M; Gawrońska-Szklarz, B; Kwiatkowski, A; Wójcicki, J, 1992
)
0.28
" Statistically significant increase of distribution volume and increase of hepatic antipyrine clearance were recorded, as well as significant shortening of half-life of this substance in the organism of tested animals in summer 1986 and 1987, compared with the remaining seasons of the year."( Seasonal variations of antipyrine pharmacokinetics parameters in calves.
Baranow-Baranowski, S; Jakubowska, D; Jankowiak, D; Janus, K; Skrzypczak, WF, 1992
)
0.82
" The antipyrine half-life proved to be the longest on the 20th day of calves' life and the shortest on the 10th and 30th day."( Pharmacokinetics of antipyrine in calves during first 35 days of life.
Baranow-Baranowski, S; Jakubowska, D; Jankowiak, D; Janus, K; Skrzypczak, WF, 1992
)
1.12
" Volume of distribution (Vd), half-life (t0."( Monthly variations in the pharmacokinetics of antipyrine in calves.
Baranow-Baranowski, S; Jakubowska, D; Jankowiak, D; Janus, K; Skrzypczak, WF, 1992
)
0.54
" There were shown statistically significant increase of half-life and decrease of metabolic clearance rate and volume of antipyrine distribution in fasted and water deprived calves."( Effect of short-term starvation and water deprivation on pharmacokinetics of antipyrine in calves.
Janus, K, 1992
)
0.72
" The measured half-life of antipyrine was 104 min and the volume of distribution was 830 mL kg-1."( The effect of intravenous pretreatment with small liposomes on the pharmacokinetics and metabolism of antipyrine in rabbits.
Al-Angary, AN; Badiola, N; Halbert, GW, 1992
)
0.8
" There were no diazepam pharmacokinetic changes during restoration period."( [Pharmacokinetics of antipyrine, nifedipine and diazepam in experimental myocardial infarct].
Anan'ev, EA; Grek, OR; Kolpakov, MA; Sharapov, VI, 1992
)
0.6
" The pharmacokinetics of ticlopidine, a novel antithrombotic agent, have been investigated in 10 healthy volunteers dosed orally with the drug (250 mg 12 hourly for 21 days), to determine the basic pharmacokinetic parameters in humans, to investigate its accumulation during repeated administration, and to assess its effects on hepatic drug-metabolizing enzymes."( Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics.
Allen, JG; Bastain, W; Dickinson, JP; Knudsen, JB; Sefton, CM, 1992
)
0.5
" The estimated pharmacokinetic values of antipyrine (AP) in EP-infected goats were similar to those in the goats when healthy."( Effects of Ehrlichia phagocytophila infection on serum thyroid hormone concentrations and on antipyrine clearance and metabolite formation in dwarf goats.
Nijmeijer, SM; Offiah, VN; van Duin, CT; van Miert, AS; Witkamp, RF, 1992
)
0.77
" Antipyrine half-life in goats (2."( Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats.
Ali, BH; Elsheikh, HA; Hapke, HJ; Hassan, T; Homeida, AM, 1991
)
1.52
" The surface area under the curve of paracetamol concentration changes was found to diminish after the bilateral removal of ovaries; there was a shortening of the half-life period for the elimination phase, and also an increase of the total clearance."( [Effect of estrogens on pharmacokinetics of phenazone and N-acetyl-p-aminophenol].
Kwiatkowski, A, 1991
)
0.28
" The antipyrine half-life was significantly longer and clearance was significantly lower in patients with cirrhosis."( Pharmacokinetics of encainide in patients with cirrhosis.
Hoensch, HP; Mönig, H; Ohnhaus, EE; Wensing, G, 1991
)
0.8
" Pharmacokinetic parameter estimates were determined at baseline (20 to 80 hours after injury) and up to three additional times thereafter (study days 4, 7, and 14)."( Effect of neurotrauma on hepatic drug clearance.
Boucher, BA; Fabian, TC; Kuhl, DA; Robertson, JT, 1991
)
0.28
" Antipyrine half-life is used as a marker of liver microsomal enzyme function."( Antipyrine and doxycycline pharmacokinetics in patients with thyroid disorders.
Bhandarkar, SD; Desai, NK; Kshirsagar, NA; Nayak, VK; Satoskar, RS, 1991
)
2.63
" Pharmacokinetic and pharmacodynamic evaluations did not show significant interactions with cimetidine following alpidem 50 mg administration."( Effect of cimetidine on the pharmacodynamics, pharmacokinetics and biotransformation of a single oral dose of alpidem.
Bianchetti, G; Desager, JP; Harvengt, C; Hulhoven, R, 1990
)
0.28
" The total plasma clearance of antipyrine was significantly decreased by deltamethrin pretreatment (20 mg/kg and 40 mg/kg daily for 6 days prior to antipyrine administration), while the elimination half-life at beta phase, the area under the concentration-time curve and the mean residence time of antipyrine were significantly increased."( Effect of deltamethrin on antipyrine pharmacokinetics and metabolism in rat.
Anadón, A; Bringas, P; Díaz, MJ; Fernandez, MC; Martinez-Larrañaga, MR, 1991
)
0.87
" There were no statistically significant differences in the saliva pharmacokinetic parameters of antipyrine on both occassions."( An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.
Edeki, T; Johnston, A; Turner, P, 1990
)
0.72
" Pharmacokinetic variable values in elderly subjects did not differ in a clinically significant manner from those in younger subjects."( Pharmacokinetics of misoprostol in the elderly, in patients with renal failure and when coadministered with NSAID or antipyrine, propranolol or diazepam.
Karim, A; Nicholson, PA; Smith, M, 1990
)
0.49
" Similar alterations may be expected in persons with thyroid dysfunctions to whom the drugs with pharmacokinetic properties similar to phenazone are administered."( [Effect of disorders of thyroid function on phenazone pharmacokinetics].
Bolanowski, M; Gruszka, S; Orzechowska-Juzwenko, K; Szymczak, J,
)
0.13
" In order to determine the endoplasmatic reticulum enzyme function, 6-beta-hydroxycortisol excretion and antipyrine pharmacokinetic parameters were evaluated."( Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam.
Brockmeyer, NH; Goos, M; Klimek, K; Mertins, L; Ohnhaus, EE, 1990
)
0.49
" Discriminant analysis of the basal data revealed that plasma bilirubin, proteins and antipyrine half-life taken together had a strong association with mortality."( Antipyrine clearance: prognostic marker for obstructive jaundice.
Bapat, RD; Dahanukar, SA; Desai, NK; Nayak, VK; Nazareth, HM; Rege, NN; Someshwar, V, 1990
)
1.95
"The present study was designed to compare the pharmacokinetic handling of a single oral dose of nicardipine in normal subjects and in patients with hepatic cirrhosis and to compare the sensitivity of the two groups to its hypotensive effect."( The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine.
Conway, EL; Drummer, OH; Louis, WJ; McNeil, JJ; Razak, TA; Sewell, RB; Smallwood, RA, 1990
)
0.28
" The mean Cmax of 4-MAA increased linearly with dose whereas its AUC was not proportional to dose after administration of 1500 and 3000 mg."( Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium.
Bacracheva, N; Badian, M; Verho, M; Vlahov, V, 1990
)
0.28
" An antipyrine pharmacokinetic and impedance analysis of 15 healthy male subjects was performed before and on the 14th day of phenobarbital administration (i."( Bioimpedance assessment of antipyrine pharmacokinetics before and after enzyme induction.
Peterson, EL; Pilla, AM; Popovich, J; Svensson, CK; Zarowitz, BJ, 1990
)
1.13
" After pretreatment with cimetidine, the plasma clearances (CL) of AP and TMO were significantly lower and the elimination half-life (t1/2) of AP was significantly increased."( The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates.
Nakamura, K; Tanaka, E, 1989
)
0.28
" Two approaches, allometric and physiologic, may be used to adjust or scale the values of model parameters determined for a substance in one species to predict its pharmacokinetic behavior in other species."( Pharmacokinetic parameters for interspecies scaling using allometric techniques.
Hayton, WL, 1989
)
0.28
" The half-life of propranolol and lidocaine in the initial phase of elimination correlated with the degree of portal-arterial disorders in liver blood supply."( [Usefulness of the evaluation of blood supply and mass of the liver for predicting the rate of pharmacokinetics of lidocaine, propranolol and phenazone].
Becker, A; Bołdys, H; Hartleb, M; Kloc, T; Mańczyk, I, 1989
)
0.28
" It was found that in all variants of the liver denervation there occurs an increase of the period of half-life and a decrease of clearance of the drugs."( [Pharmacokinetic characteristics of drug substance in liver denervation].
Ashirmetov, AKh; Krakovskiĭ, ME,
)
0.13
" There were no overall differences observed in the elimination half-life of antipyrine, nor were there significant differences between trials in cumulative urinary excretion or fractional recovery of intact antipyrine, 4-hydroxyantipyrine, norantipyrine, or 3-hydroxymethyl antipyrine."( Lack of effect of influenza vaccine on the pharmacokinetics of antipyrine, alprazolam, paracetamol (acetaminophen) and lorazepam.
Blyden, GT; Greenblatt, DJ; Scavone, JM, 1989
)
0.75
"721 h-1), and longer elimination half-life (7."( Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
Crevoisier, C; Himberg, JJ; Pentikäinen, PJ; Välisalmi, L, 1989
)
0.28
" These pharmacokinetic experiments were repeated 10 days later to determine the effect of time after implantation on tissue-chamber distribution."( Subcutaneously implanted tissue chambers--a pharmacokinetic study.
Bourne, DW; Clarke, CR; Short, CR; Usenik, EA, 1989
)
0.28
"While the relationship between the inverse of antipyrine half-life and clearance has been shown to be approximately linear in man, a recent report indicated that there was no significant relationship between antipyrine elimination rate constant (lambda) and clearance (CL) in the rat."( Relationship between antipyrine elimination rate constant, clearance and volume of distribution in the rat.
Svensson, CK, 1987
)
0.85
" The plasma half-life and area under the plasma concentration-time curve of antipyrine were unchanged."( Potential drug interactions with misoprostol: effects on the pharmacokinetics of antipyrine and propranolol.
Bennett, PN; Fenn, GC; Notarianni, LJ, 1988
)
0.73
" The resultant 14CO2 exhalation rate time profiles have been used to derive a compartmental pharmacokinetic model for the antipyrine breath test in the rat."( The antipyrine breath test in the rat: a pharmacokinetic model.
Chenery, RJ; Lockwood, GF; Norman, SJ; Oldham, HG; Standring, P,
)
0.9
" Overall mean values of elimination half-life (11."( Simplified approaches to the determination of antipyrine pharmacokinetic parameters.
Blyden, GT; Graziano, PJ; Greenblatt, DJ; Harmatz, JS; Scavone, JM, 1988
)
0.53
" Results indicated that in females, antipyrine half-life was significantly longer on day 5 as compared with that on days 15 and 21 of the menstrual cycle."( Influence of menstrual cycle on antipyrine pharmacokinetics in healthy Indian female volunteers.
Desai, NK; Kshirsagar, NA; Nayak, VK; Satoskar, RS, 1988
)
0.83
" The mean phenazone half-life (t0."( Phenazone pharmacokinetics as an index of hepatic metabolic efficiency.
Kotlarek-Haus, S; Orzechowska-Juzwenko, K; Plamieniak, B; Wiela, A; Wolowiec, D, 1988
)
0.27
" To examine whether this effect is related to the chemical structure or pharmacokinetic characteristics of the inhibiting agent, we determined the effect of dextromethorphan (a compound which exhibits pharmacokinetic similarities to, but is chemically dissimilar from, previously studied agents) on the disposition of antipyrine."( Dextromethorphan pretreatment induces antipyrine clearance in the rat.
Svensson, CK; Ware, JA, 1988
)
0.72
"We examined the pharmacokinetics of antipyrine in the rat over an 18 month period to determine whether or not the variations in pharmacokinetic parameters previously reported exhibited a circannual rhythm."( Monthly variations in the pharmacokinetics of antipyrine in the rat: circannual rhythm or random variation?
Chong, MT; Edwards, DJ; Svensson, CK, 1988
)
0.81
" During pregnancy, the clearance of antipyrine increased and its half-life decreased in all but two instances."( Pregnancy-specific changes of antipyrine pharmacokinetics correlate inversely with changes of estradiol/progesterone plasma concentration ratios.
Dvorchik, BH; Loock, W; Nau, H; Schmidt-Gollwitzer, M, 1988
)
0.84
" It was found that the half-life of all the drugs increased and plasma clearance decreased."( [Pharmacokinetic characteristics of drugs in experimental splenectomy].
Ashirmetov, AKh; Krakovskiĭ, ME,
)
0.13
" administration of antipyrine, the systemic clearance was decreased, the volume of distribution was unchanged and the half-life was increased 48 hr after catheter implantation."( Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat.
Belpaire, FM; Bogaert, MG; Chindavijak, B; De Smet, F, 1988
)
0.84
" The metabolic clearance rate (MCR) and plasma half-life of this material were measured before and after 6 days of rifampicin treatment (600 mg/day) in seven patients with Addison's disease due to tuberculosis."( Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism.
Benker, G; Mönig, H; Ohnhaus, EE; Pagel, H; Reinwein, D; Schulte, HM, 1987
)
0.27
" The administration of a single intravenous dose of amiodarone hydrochloride, 50 mg/kg, reduced antipyrine clearance by 32% and increased the half-life by 46%."( Effect of amiodarone and desethylamiodarone on the pharmacokinetics of antipyrine in the rat.
Knowlton, PW; Liu, LL; Svensson, CK, 1987
)
0.72
"0% enflurane in air resulted in a 173 and a 206% increase, respectively, in antipyrine plasma half-life and a 29."( Effect of inhalation anesthetics on antipyrine pharmacokinetics of mice.
Kooistra, KL; Moses, CJ; Powis, G; Van Dyke, RA, 1987
)
0.78
" The half-life of chlorpropamide was significantly shorter in the patients (34."( Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination.
Kärkkäinen, S; Lehtovaara, R; Neuvonen, PJ, 1987
)
0.27
" The median difference of ICG clearance and all antipyrine pharmacokinetic parameters from smoking control was less than 13%, indicating that short-term smoking withdrawal had no effect large enough to be of clinical significance on hepatic blood flow or hepatic drug-metabolizing capacity."( The effect of acute withdrawal from cigarette smoking on indocyanine green and antipyrine clearance.
Eldon, MA; Luecker, PW; MacGee, J; Ritschel, WA, 1987
)
0.76
" The intravenous antipyrine test demonstrated an unusually short half-life (5."( Large theophylline requirements due to high theophylline clearance: verification by the antipyrine test.
Blyden, GT; Greenblatt, DJ; LeDuc, BW, 1986
)
0.83
" Antipyrine half-life was slightly but not significantly shortened and the antipyrine clearance was essentially identical in the whole study."( Ketoconazole does not impair antipyrine clearance in humans.
Abernethy, DR; Blyden, GT; Greenblatt, DJ, 1986
)
1.47
"01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13."( The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
Bach, D; Blevins, R; Edwards, DJ; Kerner, N; Rubenfire, M, 1986
)
0.81
" The pharmacokinetic parameters of molsidomine were similar to already published data in healthy volunteers and patients."( Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
Chamberlain, J; Gärtner, W; Ostrowski, J; Stockhausen, H; Wildgrube, HJ, 1986
)
0.27
" The mean phenazone half-life time (t0."( Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone.
Cieślińska, A; Orzechowska-Juzwenko, K; Roszkowska, E; Wiela, A, 1987
)
0.27
"Various pharmacokinetic parameters--disposition half-life, t1/2,z, metabolic clearance CLm, volume of distribution V, intrinsic clearance of unbound drug CLuint, and unbound volume of distribution of tissues (distributive tissue volume/fraction of drug in tissue unbound, VT/fuT--are compared in rat and human for nine weakly acidic drugs, phenytoin, hexobarbital, pentobarbital, phenylbutazone, warfarin, tolbutamide, valproate, phenobarbital, and amobarbital, and six weakly basic drugs, quinidine, chlorpromazine, propranolol, pentazocin, antipyrine, and diazepam."( Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.
Hanano, M; Iga, T; Sawada, Y; Sugiyama, Y, 1985
)
0.43
" Phenobarbital bolus doses and infusion rates were based on a preliminary pharmacokinetic study (7 rats) and were varied to achieve a broad range of steady state levels."( Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat.
Bialer, M; Levy, RH; Pei, YY,
)
0.39
" In comparison to a control group of subjects (n = 6), patients with early (active) schistosomiasis (passing live ova in urine or stools without clinical and laboratory evidence of liver involvement; n = 6) exhibited similar pharmacokinetic parameters."( The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.
Back, DJ; el-Raghy, I; Nafeh, MA; Orme, ML; Osman, F, 1985
)
0.58
"Antipyrine salivary clearance and half-life and the rate of formation of three principal metabolites of antipyrine (4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norantipyrine) were assessed in nine children with congenital adrenal hyperplasia, six of whom were salt-losers and three of whom were non-salt-losers."( Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.
Breimer, DD; Bruining, GJ; De Jongh, BM; Tenkate-Westerhof, EW; Teunissen, MW, 1985
)
3.15
" The clearance of both antipyrine and d-propranolol was increased and the half-life decreased significantly by phenobarbital."( Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
Branch, RA; Nies, AS; Shand, DG; Wilkinson, GR, 1974
)
0.87
"Pronounced differences in pharmacokinetic parameters of antipyrine have been found in the 20-day pregnant hooded Wistar rat when compared with nonpregnant controls."( Antipyrine pharmacokinetics in the pregnant rat.
Dean, M; O'Donnell, L; Penglis, S; Stock, B,
)
1.82
" Mean triazolam elimination half-life was not significantly different between young and elderly men (3."( Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Moschitto, LJ; Shader, RI; Smith, RB, 1983
)
0.51
"The advantages and limitations of the 2 most commonly used methods to investigate interindividual pharmacokinetic variations are reviewed."( Assessment of methods to identify sources of interindividual pharmacokinetic variations.
Penno, MB; Vesell, ES,
)
0.13
" The magnitude of the variation was three fold for the serum half-life and body clearance and two fold for the apparent volume of distribution."( Monthly variations in the clearance of antipyrine in the rat.
Bélanger, PM; Doré, F; Labrecque, G, 1984
)
0.54
" After rifampicin treatment the elimination half-life of antipyrine had decreased in all patients from 12."( Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.
Bakker, W; Breimer, DD; Meerburg-Van der Torren, JE; Teunissen, MW, 1984
)
0.79
"The pharmacokinetic parameters of antipyrine (AP) were examined in 45 normal healthy subjects (18 heavy smokers, 5 mild smokers, and 22 nonsmokers) and in 12 patients with Gilbert's syndrome (GS), amongst whom 2 mild and 1 heavy smokers were included."( Antipyrine clearance in patients with Gilbert's syndrome.
Chiba, K; Ishizaki, T; Sasaki, T, 1984
)
1.99
" There were no significant differences in the biological half-life (T1/2), the apparent volume of distribution (Vd), and the clearance (C) of antipyrine and paracetamol."( Pharmacokinetics of antipyrine, paracetamol, and morphine in rat at 71 ATA.
Aanderud, L; Bakke, OM, 1983
)
0.79
"69 liter/kg), elimination half-life (12."( Ibuprofen does not impair antipyrine clearance.
Abernethy, DR; Greenblatt, DJ,
)
0.43
" In vitro findings suggest that the most probable cause of delayed clearance/prolonged half-life and increased AUCoral values was the reduction in hepatic cytochrome P-450 dependent mixed function oxidase system."( The effect of anti-cancer drugs on pharmacokinetics of antipyrine in vitamin A deficiency.
Dogra, SC; Kaushal, S; Khanduja, KL; Sharma, RR, 1984
)
0.51
" The mean plasma half-life of antipyrine was 10."( The influence of vitamin C on antipyrine pharmacokinetics in elderly men.
Achari, R; Blanchard, J; Conrad, KA; Harrison, GG,
)
0.71
" In the control state, antipyrine half-life was longer in elderly than in young subjects (16."( Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Shader, RI, 1982
)
0.86
" Cimetidine inhibited MISO demethylation and increased its half-life and area under the curve."( Effects of cimetidine, antipyrine, and pregnenolone carbonitrile on misonidazole pharmacokinetics.
Donaldson, J; Smith, NC; Workman, P,
)
0.44
" Paracetamol, the only metabolised drug which is conjugated for which pharmacokinetic parameters have been accurately determined in obesity, undergoes increased clearance in obese subjects."( Pharmacokinetics of drugs in obesity.
Abernethy, DR; Greenblatt, DJ,
)
0.13
") antipyrine half-life in patients with jaundice was 21."( Antipyrine clearance, aminopyrine N-demethylase, and bilirubin UDP-glucuronyl transferase activity in patients with amoebic liver abscess.
Datta, DV; Mathur, VS; Narang, AP,
)
2.3
"The assay procedure described in this paper allows the calculation of pharmacokinetic data of antipyrine disposition to be obtained from a single animal with minimal disturbance in hematocrit."( A rapid gas-liquid chromatographic determination of antipyrine clearance in the rat.
Adams, JF; Cousins, MJ; Gourlay, GK; Knights, KM, 1981
)
0.73
"The half-life and metabolic clearance rate (MCR) of antipyrine and phenytoin were determined in 14 young (mean age: 28."( Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
Bach, B; Hansen, JM; Kampmann, JP; Rasmussen, SN; Skovsted, L,
)
0.73
"001), and antipyrine half-life was reduced by 42% (10."( Antipyrine clearance in surgical patients maintained on hypocaloric peripheral parenteral nutrition.
Almar, M; Culebras, JM; Gonzalez-Gallego, J; Gonzalez-Sastre, M; Jorquera, F; Martinez, C,
)
1.98
"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6."( Caffeine pharmacokinetics in obesity and following significant weight reduction.
Berry, EM; Caraco, Y; Levy, M; Zylber-Katz, E, 1995
)
0.29
" A decision was made to examine the pharmacokinetic parameters, independent of compartmental analysis of verapamil and its active metabolite norverapamil, in patients with portal hypertension."( Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy.
Brátová, M; Fendrich, Z; Hůlek, P; Macek, K; Vlcek, J, 1995
)
0.29
" The identity of pharmacokinetic regularities of antipyrin in samples of blood plasma and saliva permit the use of saliva as biological material for assessment of the metabolic profile of pregnant women."( [A prospective study of antipyrine pharmacokinetics in pregnancy].
Asymbekova, GU, 1995
)
0.6
" However, changes in pharmacokinetic parameters of elimination from the blood of the drugs based on microsomal substrates of hepatic enzymatic system are more dependent on the microwaves' impact on physiological factors modifying drug pharmacokinetics."( [The characteristics of the effect of centimeter-range microwaves on drug pharmacokinetics in the body of experimental animals].
Gorchakova, GA; Grishanova, AIu; Guliaeva, LF; Liakhovich, VV; Zolotareva, TA,
)
0.13
"Rats are commonly isolated individually in cages during pharmacokinetic studies."( Metabolic cage isolation reduces antipyrine clearance in rats.
Brunner, LJ; Dipiro, JT; Feldman, S, 1994
)
0.57
" The pharmacokinetic interactions between paracetamol (PA) and antipyrine (AP) were studied in pigs in order to investigate the usefulness of this combination for the simultaneous assessment of oxidative and conjugative metabolism."( Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig.
Monshouwer, M; Pijpers, A; van Miert, AS; Verheijden, JH; Witkamp, RF, 1994
)
0.78
" Bilharzial infestation caused a significant reduction in the elimination (beta) and clearance rate (Cl) of antipyrine, whereas its elimination half-life (t1/2 beta) was increased in comparison with the normal controls."( Pharmacokinetic profile of methotrexate and 5-fluorouracil in normal and bilharzial-infested mice.
el-Aaser, AB; el-Merzabani, MM; Osman, AM; Saad, SF; Saad, SY,
)
0.34
" This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2."( Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats.
Clark, CR; Ferry, DG; Kepple, M; Nyika, S; Wanwimolruk, S, 1993
)
0.77
" Four distinct antipyrine pharmacokinetic tissue compartments and the distribution clearances assigned to them could be estimated: a pulmonary tissue (0."( A recirculatory pharmacokinetic model describing the circulatory mixing, tissue distribution and elimination of antipyrine in dogs.
Avram, MJ; Henthorn, TK; Krejcie, TC; Shanks, CA, 1994
)
0.85
" A Bayesian approach was developed to determine the individual pharmacokinetic parameters of phenazone."( Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.
Bouvet, O; Bressolle, F; Dubois, A; Fabre, D; Galtier, M; Goméni, R; Gris, JC; Raffanel, C, 1993
)
0.49
" Pharmacokinetic parameters of antipyrine were evaluated before surgery and within 10 d after surgery."( Pharmacokinetic parameters of antipyrine in dog after hepatectomy.
Bressolle, F; Briand, D; Fabre, D; Galtier, M; Gomeni, R; Pinguet, F, 1995
)
0.87
" On the base of these experiments there was able to make a conclusion that estrogens influence on the phenazone's pharmacokinetic probably by induction of microsomal enzymes of liver."( [Effect of mestranol on pharmacokinetics of phenazone in the rabbit].
Droździk, M; Gawrońska-Szklarz, B; Kwiatkowski, A; Wójcicki, J, 1996
)
0.29
" The first three months of life were characterised by a steady decrease in the apparent volume of distribution (aVd) and half-life (t0."( Effect of age on the pharmacokinetics of antipyrine in calves.
Janus, K; Suszycka, J, 1996
)
0.56
" Mean ClAP was reduced by 38% and antipyrine half-life increased by 64% in old subjects."( Effects of aging on antipyrine clearance: predictive factors of metabolizing capacity.
Almar, MM; González-Gallego, J; González-Sastre, M; Jorquera, F; Pozuelo, M; Sansegundo, D, 1995
)
0.89
" Terminal half-life (t1/2), was significantly longer in nonascitic patients than in control subjects (32 vs 22 min)."( Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
Ferrara, SD; Frison, G; Mazzo, M; Orlando, R; Padrini, R; Palatini, P; Tedeschi, L; Zordan, R, 1996
)
0.29
" laboratory and pharmacodynamic tests, as well as pharmacokinetic assays, were performed before the operation as well as 10-12 days after the bile duct ligation."( Pharmacokinetics of phenazone (antipyrine) in rabbits with experimental common bile duct obstruction.
Barcew-Wiszniewska, B; Droździk, M; Gawrońska-Szklarz, B; Rózewicka, L; Skowron, J; Sulikowski, T; Wójcicki, J; Wójcicki, M, 1996
)
0.58
" However, total plasma clearance (CL), steady-state volume of distribution, area under the concentration-time curve [AUC(0-infinity)], and elimination half-life of butorphanol in patients with hepatic impairment were significantly altered (approximately twofold to threefold)."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
"Based on the comparable Cmax but the increased AUC in patients with liver dysfunction, the initial dose of butorphanol nasal spray may not need to be adjusted."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
"The purpose of this study was to evaluate the validity of the one-sample abbreviated method for determination of the pharmacokinetic parameters of antipyrine in the elderly."( Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects.
Almar, MM; González-Gallego, J; González-Sastre, M; Jorquera, F; Suarez, I, 1996
)
0.74
" In cigarette smoking, non-oral contraceptive users versus controls, elimination half-life was reduced (8."( Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics.
Abernethy, DR; Greenblatt, DJ; Harmatz, JS; Luna, BG; Scavone, JM; Shader, RI, 1997
)
0.52
" The half-life of sulphadimidine was also significantly prolonged 5, 9 and 16 weeks after infection."( The effect of experimental fascioliasis on the pharmacokinetics of antipyrine and sulphadimidine in desert sheep.
Ali, BH; Elsheikh, HA, 1997
)
0.53
" In order to determine the microsomal enzyme activity, the 6-beta-hydroxycortisol/17-hydroxycorticosteroid ratio and antipyrine pharmacokinetic parameters were determined."( Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
Barthel, B; Brockmeyer, NH; Goos, M; Mertins, L; Tillmann, I, 1997
)
0.51
" The pharmacokinetic properties of dihydroquinine were generally similar to those of quinine, although dihydroquinine clearance was less affected by acute malaria."( A study of the factors affecting the metabolic clearance of quinine in malaria.
Davis, TM; Keeratithakul, D; Kyle, D; Looareesuwan, S; Nagachinta, B; Pukrittayakamee, S; Smith, AL; Teja-Isavadharm, P; Weber, A; White, NJ, 1997
)
0.3
" Marker dispositions were described by recirculatory pharmacokinetic models based on frequent early and less frequent later arterial blood samples."( The effect of halothane on the recirculatory pharmacokinetics of physiologic markers.
Avram, MJ; Gentry, WB; Henthorn, TK; Klein, C; Krejcie, TC; Niemann, CU; Shanks, CA, 1997
)
0.3
" Recirculatory pharmacokinetic models include the best aspects of traditional compartmental and physiologic pharmacokinetic models while offering advantages over both."( The effect of halothane on the recirculatory pharmacokinetics of physiologic markers.
Avram, MJ; Gentry, WB; Henthorn, TK; Klein, C; Krejcie, TC; Niemann, CU; Shanks, CA, 1997
)
0.3
" No significant differences were found between the pre- and post-partum systemic plasma clearance, steady-state volume of distribution or terminal plasma half-life of zalcitabine, indicating that pregnancy does not affect the pharmacokinetics of the drug in the macaque."( Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina).
Nosbisch, C; Tuntland, T; Unadkat, JD, 1997
)
0.3
"The effect of water deprivation on the pharmacokinetic parameters of antipyrine and sulphadimidine in the Nubian goat was studied."( The effect of water deprivation on the pharmacokinetics of antipyrine and sulphadimidine following intravenous administration in Nubian goats.
Abdullah, AS; Elsheikh, HA; Osman, IA, 1997
)
0.77
" Antipyrine was administered orally and pharmacokinetic parameters were obtained from saliva samples by the multiple-sample method."( The effect of physical conditioning on antipyrine clearance.
Bayón, JE; Cuadrado, G; González-Gallego, J; Villa, JG, 1998
)
1.48
" No differences were observed in lorazepam pharmacokinetic parameters."( Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
Adams, MH; Ferry, JJ; Garnett, WR; Karnes, HT; Poynor, WJ; Ryan, KK; Sarkar, MA, 1998
)
0.3
" In the absence of multiple-dose minoxidil pharmacodynamic studies in this population, minoxidil should be used as in other populations: begin with a modest dose, and adjust the dose based on clinical response."( Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
Adams, MH; Ferry, JJ; Garnett, WR; Karnes, HT; Poynor, WJ; Ryan, KK; Sarkar, MA, 1998
)
0.3
" We measured in vivo pharmacokinetic parameters of antipyrine in rats treated with endotoxin and/or a selective inhibitor of inducible NO synthase (iNOS), S-methylisothiourea."( Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide.
Hasegawa, T; Iwase, M; Kitaichi, K; Nadai, M; Shibata, E; Takagi, K; Wang, L, 1999
)
0.96
" Marker and drug dispositions were described by recirculatory pharmacokinetic models based on frequent early and less-frequent later arterial blood samples."( Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective.
Avram, MJ; Enders-Klein, C; Henthorn, TK; Krejcie, TC; Niemann, CU; Shanks, CA, 1999
)
0.3
"Several statistical regression models and artificial neural networks were used to predict the hepatic drug clearance in humans from in vitro (hepatocyte) and in vivo pharmacokinetic data and to identify the most predictive models for this purpose."( Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Coassolo, P; Lavé, T; Schneider, G, 1999
)
0.3
" The plasma elimination half-life of antipyrine was significantly elevated by 23% at 11 weeks postinfection (p."( Effect of experimental fasciolosis on antipyrine metabolism and clearance in water buffaloes.
Bayón, JE; Ferre, I; González-Gallego, J; Jiang, SX; Mao, XZ, 2000
)
0.85
" On day 5 there were no statistically significant differences in the Cmax or tmax for ziprasidone between the two groups."( The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.
Anderson, KE; Anziano, RJ; Bauer, LA; Carithens, RL; Everson, G; Johnson, A; Lasseter, KC; Smolarek, TA; Turncliff, RZ; Wilner, KD, 2000
)
0.31
" Marker dispositions were described by recirculatory pharmacokinetic models based on very frequent early, and less frequent later, arterial blood samples."( Isoflurane alters the recirculatory pharmacokinetics of physiologic markers.
Avram, MJ; Enders-Klein, C; Henthorn, TK; Krejcie, TC; Niemann, CU; Shanks, CA, 2000
)
0.31
" These results indicate that compounds showing poor oral bioavailability can be excluded before in vivo pharmacokinetic study by using this method."( A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum.
Ishii, Y; Shibata, Y; Takahashi, H, 2000
)
0.31
" Twenty-four hours after LPS injection, the pharmacokinetic parameters of the four drugs were obtained following intravenous administrations of antipyrine (7 mg/kg), theophylline (5 mg/kg), phenytoin (10 mg/kg) and nifedipine (1 mg/kg)."( The impact of acute phase response on the plasma clearance of antipyrine, theophylline, phenytoin and nifedipine in rabbits.
Kokue, E; Saitoh, T; Shimoda, M, 2000
)
0.75
"Recirculatory pharmacokinetic models for indocyanine green (ICG), inulin, and antipyrine facilitate description of intravascular mixing and tissue distribution following intravenous administration."( Drug-induced hemodynamic perturbations alter the disposition of markers of blood volume, extracellular fluid, and total body water.
Avram, MJ; Krejcie, TC; Wang, Z, 2001
)
0.54
" When compared to patients in stage I, patients in advanced stages showed a reduction in antipyrine clearance (-29% and -44% in stages III and IV, respectively) and increases in antipyrine half-life (+24% and +75% in stages III and IV, respectively)."( Antipyrine clearance and metabolite formation in primary biliary cirrhosis.
Almar, M; González-Gallego, J; Jorquera, F; Linares, A; Olcóz, JL; Rodrigo, L, 2001
)
1.98
" The oral pharmacokinetic profiles of ABT were generated in rats, dogs, and monkeys in the dose range of 5 to 200 mg/kg."( Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.
Balani, SK; He, B; Lee, FW; Liu, Z; Yang, TJ; Zhu, T, 2002
)
0.55
" Mean values for elimination half-life and mean residence time of penicillin G were significantly higher in emus than in ostriches; no significant differences in antipyrine pharmacokinetics between species were demonstrated."( Intravenous pharmacokinetics of penicillin G and antipyrine in ostriches (Struthio camelus) and emus (Dromaius novaehollandiae).
Clarke, CR; Cudd, LA; Kocan, AA; Wang, Z; Webb, AI, 2001
)
0.76
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" The projected P450 inactivations at the plasma Cmax of ABT agreed with the inhibitions of P450-mediated AP clearance observed in vivo."( Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling.
Balani, SK; Cardoza, K; Gan, LS; Lee, FW; Li, P; Mu, DX; Nguyen, J; Wu, JT; Zeng, H, 2004
)
0.56
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
"Quantitative structure-pharmacokinetic relationships (QSPkR) have increasingly been used for the prediction of the pharmacokinetic properties of drug leads."( Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods.
Chen, YZ; Li, ZR; Yap, CW, 2006
)
0.33
", 3 days) decreased the antipyrine clearance (30-35%), with an increase in the plasma half-life (T1/2) by 55% and an increase in the area under concentration-time curve (AUC) by 61%."( Modulation of antipyrine clearance by polysaccharide peptide (PSP) isolated from Coriolus versicolor in the rat.
Chan, SL; Yeung, JH, 2006
)
1
" Alfentanil pharmacokinetics (plasma concentration, area under the plasma concentration-time curve from time zero to infinity [AUC(infinity(p))] and from time zero to 2 hours [AUC(2(p))], apparent volume of distribution at steady state, clearance and terminal elimination half-life [t((1/2)(p))]) and miosis pseudo-kinetic parameters [AUC(infinity)((miosis)), AUC(2)((miosis)), t((1/2))((miosis))] were determined using a noncompartmental analysis method."( Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan, N; Desager, JP; Horsmans, Y; Starkel, P; Van Obbergh, L; Verbeeck, RK; Wallemacq, P, 2007
)
0.34
"Alfentanil pharmacokinetic parameters were correlated with miosis pseudo-kinetic parameters in cirrhotic patients."( Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan, N; Desager, JP; Horsmans, Y; Starkel, P; Van Obbergh, L; Verbeeck, RK; Wallemacq, P, 2007
)
0.34
" There were no differences in the disposition or pharmacokinetic parameters for inulin between the dog breeds."( Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs.
Coetzee, JF; Gehring, R; Hubin, M; KuKanich, B, 2007
)
0.34
" The pharmacokinetic variables for antipyrine were determined using the two concentration time points selected."( Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
Abdel-Kader, R; Botros, S; Hassanein, M; Mahmoud, M; Saleh, S, 2007
)
2.06
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The transplacental pharmacokinetic model was fitted to the time profiles of the drug concentrations in the effluent and placenta to obtain transplacental pharmacokinetic parameters."( Transplacental pharmacokinetics of diclofenac in perfused human placenta.
Fujii, T; Hori, S; Nagata, H; Nakano, H; Ohtani, H; Satoh, S; Sawada, Y; Shintaku, K; Taketani, Y; Tsujimoto, M; Tsukimori, K, 2009
)
0.35
"The aim was to investigate the pharmacokinetic interaction between puerarin and edaravone, and the effect of borneol on the brain distribution kinetics of puerarin in rats."( Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats.
Gao, C; Li, X; Li, Y; Wang, L; Xue, M, 2010
)
0.36
" The detection method was successfully applied to compare the pharmacokinetic interaction and brain distribution kinetics of puerarin and edaravone using in-situ microdialysis sampling in rats after intravenous administration and co-administration with a single dose."( Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats.
Gao, C; Li, X; Li, Y; Wang, L; Xue, M, 2010
)
0.36
" Studies were undertaken using an in situ-perfused rat liver and multiple indicator dilution, and outflow data were analyzed with a physiologically based organ pharmacokinetic model."( Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Thorling, CA; Zhang, Q, 2011
)
0.37
" This study evaluated the effect of simulated weightlessness on gender-related pharmacokinetic differences of intravenously administered antipyrine, a marker compound for hepatic oxidative metabolism, using the tail-suspended (TS) rat model for microgravity."( Gender differences in pharmacokinetics of antipyrine in a simulated weightlessness rat model.
Abobo, CV; Liang, D; Ma, J; Wei, B, 2012
)
0.85
" Plasma antipyrine concentration-time data were analyzed using noncompartmental pharmacokinetic methods."( Gender differences in pharmacokinetics of antipyrine in a simulated weightlessness rat model.
Abobo, CV; Liang, D; Ma, J; Wei, B, 2012
)
1.08
" Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique."( Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012
)
0.38
" Hepatic pharmacokinetic analysis showed that both the CL int and PS were significantly decreased in the RHF rat livers."( Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012
)
0.38
" We characterized the transplacental transfer of paroxetine in perfused human placenta, fitting a pharmacokinetic model to the results and applying the model and parameters to evaluate a tapered dosage regimen."( Characterization of transplacental transfer of paroxetine in perfused human placenta: development of a pharmacokinetic model to evaluate tapered dosing.
Fujii, T; Hori, S; Matsuoka, S; Nagai, M; Ohtani, H; Satoh, H; Sawada, Y; Taketani, Y, 2013
)
0.39
" The validated methods were successfully applied to study the pharmacokinetic interaction of taurine and edaravone in rats after independent intravenous administration and co-administration with a single dose."( LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study.
Bian, TT; Du, Q; Jiang, SS; Li, Y; Li, YJ; Tang, DQ; Wu, XW; Zheng, XX, 2014
)
0.4
"In pharmacokinetic evaluation of mice, using serial sampling methods rather than a terminal blood sampling method could reduce the number of animals needed and lead to more reliable data by excluding individual differences."( Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y, 2015
)
0.42

Compound-Compound Interactions

antipyrine given with phenobarbitone produced slightly more induction than phenobarbitsone given alone. This study was designed to support the clinical trials of ALED in clinical settings in China.

ExcerptReferenceRelevance
" Omeprazole contains a benzimidazole moiety and thus has the potential to interact with the cytochrome P-450 enzyme group."( Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole.
Humphries, TJ, 1991
)
0.28
"The most widely used H2-receptor antagonist, cimetidine, is known to interact with cytochrome P-450 drug-metabolizing enzymes and, therefore, interacts with other drugs which may be administered concurrently."( Comparative effects of H2-receptor antagonists on drug interaction in rats.
Cocchetto, DM; Duggan, DE; Lin, JH; Yeh, KC,
)
0.13
"Propranolol is widely used in clinical practice and is frequently administered along with other drugs."( Pharmacokinetic drug interactions with propranolol.
Feely, J; Wood, AJ,
)
0.13
" Based on previous studies, antipyrine given with phenobarbitone produced slightly more induction than phenobarbitone given alone."( Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man.
Gerber-Taras, E; Ohnhaus, EE; Park, BK, 1983
)
0.56
" Different mechanisms have to be considered as causes for potential drug-drug interactions."( Lack of pantoprazole drug interactions in man.
Bliesath, H; Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW; Wurst, W; Zech, K, 1994
)
0.29
"The aim of the study was to investigate whether the analgesic effect of propyphenazone (PROP) was increased when it was administered in combination with caffeine (CAFF)."( Analgesic effects of propyphenazone in comparison to its combination with caffeine.
Hummel, T; Kobal, G; Kraetsch, HG; Kussat, R; Lötsch, J, 1996
)
0.29
" No significant differences between plasma levels of PROP were found when applied either alone or in combination with CAFF."( Analgesic effects of propyphenazone in comparison to its combination with caffeine.
Hummel, T; Kobal, G; Kraetsch, HG; Kussat, R; Lötsch, J, 1996
)
0.29
"The efficacy of hyperbaric oxygen (HBO) therapy combined with intravenous edaravone (free radical scavenger) administration was prospectively investigated in patients with acute embolic stroke involving the anterior cerebral circulation."( Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial.
Imai, K; Izumoto, H; Kunieda, T; Mori, T; Takabatake, N; Watanabe, M, 2006
)
0.33
" In addition, using serial sampling methods can be valuable for evaluation of the drug-drug interaction (DDI) potential of drug candidates."( Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y, 2015
)
0.42
"This study was designed to assess the preclinical toxicity of antipyrine combined with lidocaine hydrochloride ear drops (ALED) and support the clinical trials of ALED in clinical settings in China."( Preclinical safety assessment of antipyrine combined with lidocaine hydrochloride as ear drops.
Ba, JB; Chu, ZY; Feng, X; Liu, WH; Zhang, XD; Zou, YX, 2019
)
1.04

Bioavailability

The effects of hepatic and presystemic enzyme induction on the bioavailability (F) and disposition of antipyrine after repeated rifampicin (RFM) and rifabutin ( RBT) exposure were studied in mice. Absolute bioavailability of an aqueous solution of antipyrsine was on average 97%.

ExcerptReferenceRelevance
" No consistent change due to bed rest was found in the rate of absorption or bioavailability of the oral dose."( Influence of bed rest on the pharmacokinetics of phenazone.
Elfström, J; Lindgren, S, 1978
)
0.26
"The influence of food intake on the bioavailability of three analgesic compounds--propoxyphene chloride, acetyl salicylic acid and phenazone--in a combination tablet, Doleron, has been examined in eight healthy volunteers."( Bioavailability of D-propoxyphene, acetyl salicylic acid, and phenazone in a combination tablet (Doleron): interindividual variation and influence of food intake.
Berlin-Wahlén, A; Bodin, NO; Danielson, K; Gustafsson, B; Lindgren, S; Melander, A; Westerlund, D, 1977
)
0.26
"Seventeen patients with intestinal shunt for obesity and 11 control patients were given 15 mg phenazone per kg perorally to estimate the rate of absorption and hepatic metabolism of phenazone."( Drug absorption and hepatic drug metabolism in patients with different types of intestinal shunt operation for obesity. A study with phenazone.
Andreasen, PB; Danö, P; Greisen, G; Kirk, H, 1977
)
0.26
" Fasting reduced the absorption rate constants for both drugs with the salicylate rates being depressed more severely than the rates for antipyrine."( The effect of fasting on the rate of intestinal drug absorption in rats: preliminary studies.
Benet, LZ; Orr, JM, 1975
)
0.46
" route showed an oral bioavailability of 54 +/- 12%, whereas for those first dosed by the oral route the calculated bioavailability was 31 +/- 6%."( Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat.
Aristorena, JC; Chesa-Jiménez, J; Garcia-Carbonell, C; Granero, L; Peris-Ribera, JE; Pla-Delfina, J; Torres-Molina, F, 1992
)
0.5
" The bioavailability of the intravesical dose was calculated using the clearance of [14C]antipyrine and the plasma concentrations of unlabeled antipyrine."( Evidence of significant absorption of antipyrine from urinary bladder of rats.
Au, JL; Dalton, JT; Harrington, MD, 1992
)
0.78
" The relative bioavailability for these two types of tablets pointed out the differences, confirming the evident advantages for using the lyoc tablets in analgesic, antipyretic therapy."( [Formulations and bioavailability of propyphenazone in lyophilized tablets].
Antochi, S; Dumistrăcel, I; Gafiţanu, E,
)
0.13
" Thus, encainide bioavailability was increased in cirrhosis."( Pharmacokinetics of encainide in patients with cirrhosis.
Hoensch, HP; Mönig, H; Ohnhaus, EE; Wensing, G, 1991
)
0.28
" Of these, 11 thyrotoxic and 9 euthyroid goitre patients also participated in doxycycline bioavailability studies."( Antipyrine and doxycycline pharmacokinetics in patients with thyroid disorders.
Bhandarkar, SD; Desai, NK; Kshirsagar, NA; Nayak, VK; Satoskar, RS, 1991
)
1.72
" administration of the beta blockers, no significant increase in area under the plasma drug concentration-time curve was observed for propranolol and metoprolol as a function of age, but for atenolol, a significant increase in area under the plasma drug concentration-time curve was seen in the 24-month-old rats, due to a decrease in renal function, as bioavailability of atenolol did not change in function of age."( Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat.
Belpaire, FM; Bogaert, MG; Chauvelot-Moachon, L; de Smet, F; Rosseel, MT; Vermeulen, AM; Vynckier, LJ, 1990
)
0.28
" Despite complete AP absorption, absolute bioavailability of AP was 78 +/- 12% under basal conditions, suggesting that AP does undergo some degree of presystemic elimination, approximately 22%."( On the antipyrine test in laboratory animals. Studies in the dog and monkey.
Bowman, TA; Dvorchik, BH; Hughes, DM; Passananti, GT; Vesell, ES; Vickers, FF,
)
0.59
" Propranolol bioavailability correlated with the diameter of the portal vein and was dependent on the size of oesophageal varices and the presence of cavernous transformation of the portal vein."( [Usefulness of the evaluation of blood supply and mass of the liver for predicting the rate of pharmacokinetics of lidocaine, propranolol and phenazone].
Becker, A; Bołdys, H; Hartleb, M; Kloc, T; Mańczyk, I, 1989
)
0.28
" CBZ-CR fulfils the criteria for a controlled-release preparation with comparable apparent bioavailability to CBZ-C."( A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.
Brodie, MJ; Butler, E; Larkin, JG; McLellan, A; Munday, A; Sutherland, M, 1989
)
0.28
" Excellent bioavailability of theophylline was confirmed from paired oral and intravenous tests in seven subjects, including two with exocrine pancreatic failure."( Factors contributing to the accelerated clearance of theophylline and antipyrine in adults with exocrine pancreatic disease.
Acheson, DW; Braganza, JM; Houston, JB; Hunt, LP; Rose, P, 1989
)
0.51
" If these results were extrapolated to humans, they would explain the excellent bioavailability profiles reported for baclofen at normal doses in spite of its physicochemical properties, which do not favour passive diffusion."( Evidence of a specialized transport mechanism for the intestinal absorption of baclofen.
Casabó, VG; García-Carbonell, MC; Martín-Villodre, A; Merino, M; Peris-Ribera, JE; Plá-Delfina, JM; Sánchez-Picó, A; Torres-Molina, F,
)
0.13
" Absolute bioavailability of oral chlordiazepoxide was not less than 100%, and was unrelated to age or sex."( Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition.
Abernethy, DR; Divoll, MK; Greenblatt, DJ; Harmatz, JS; Ochs, HR; Shader, RI, 1989
)
0.51
"Felodipine is a dihydropyridine calcium antagonist, structurally related to nifedipine, which undergoes extensive first-pass hepatic metabolism and normally has an oral bioavailability of 15%."( Reduced felodipine bioavailability in patients taking anticonvulsants.
Capewell, S; Critchley, JA; Freestone, S; Pottage, A; Prescott, LF, 1988
)
0.27
" The simultaneous increase in intraluminal pressure and radius resulted in a linear relation between absorption rate and apparent mucosal surface area."( Influence of dietary fiber and intraluminal pressure on absorption and pre-epithelial diffusion resistance (unstirred layer) in rat jejunum in situ.
Holzheimer, G; Winne, D, 1986
)
0.27
" The bioavailability of antipyrine was only 20% due to first-pass metabolism."( The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog.
Abramson, FP,
)
0.66
" Absolute bioavailability was not significantly less than 100% and was not related to age."( Antipyrine absorption and disposition in the elderly.
Divoll, MK; Greenblatt, DJ; Harmatz, JS; Shader, RI, 1988
)
1.72
"The concomitant administration of hydralazine with metoprolol or propranolol substantially increases the oral bioavailability of these beta-blockers, presumably via reduction of the first-pass effect."( Effect of hydralazine on the elimination of antipyrine in the rat.
Knowlton, PW; Svensson, CK; Ware, JA, 1987
)
0.53
"4 ml min-1 g-1 by constriction or release of the mesenteric artery decreased or increased the absorption rate of antipyrine."( Relationship between antipyrine absorption and blood flow rate in rat jejunum, ileum, and colon.
Schulz, R; Winne, D, 1987
)
0.8
" The bioavailability of oleaginous base and water-soluble base (polyethylene glycol 4000) were 44."( Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit.
Itoh, S; Morishita, N; Sawanoi, M; Suginaka, A; Tanabe, K; Yamazaki, M, 1987
)
0.27
" Bioavailability was essentially complete (mean bioavailability 101."( Pharmacokinetics of antipyrine in epileptic patients.
Richens, A; Rimmer, EM; Routledge, PA; Tsanaclis, LM, 1986
)
0.59
"The examination of the bioavailability from 4 different preparations of propyphenazone suppositories on a fatty base, studied in 10 healthy volunteers, showed bioequivalence as was judged by means of the AUC-values."( [Availability of propylphenazone from suppositories. 2. Bioavailability].
Bornschein, M; Dietzsch, B; Gabrio, T; Grune, D; Hackenberger, F; Voigt, R, 1986
)
0.27
" The knowledge of pharmacokinetics give essential informations for the development of new pharmaceutical forms, adjustment of dosage regimen and recommendations for drug intake in order to minimize the variations in bioavailability and to improve compliance."( [Pharmacokinetics: a contribution in clinical geriatric pharmacology?].
Humbert, H; Kiechel, JR; Lavène, D, 1983
)
0.27
" Chloramphenicol also was administered to older calves by IM and subcutaneous routes, with an apparent bioavailability of 50% to 60%."( Chloramphenicol and the neonatal calf.
Barto, PB; Burrows, GE; Craigmill, AL; Tyler, RD, 1984
)
0.27
" The net result was that the comparative bioavailability of the drug was higher in PEM as compared to the control."( Disposition of four drugs in malnourished children.
Mathur, VS; Mehta, S; Nain, CK; Sharma, B, 1982
)
0.26
"Physico-chemical properties, dissolution profiles, and bioavailability of the molecular compound composed of equimolar amount of 1-benzenesulfonyl-5, 5-diphenylhydantoin (BSDH) and antipyrine were studied."( Biopharmaceutical studies on hydantoin derivatives. III. Physico-chemical properties, dissolution behavior, and bioavailability of the molecular compound of 1-benzenesulfonyl-5,5-diphenylhydantoin and antipyrine.
Fujioka, H; Tan, T, 1982
)
0.64
" Data from both plasma and saliva showed that the oral bioavailability of antipyrine given as an aqueous solution was complete."( Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
Boeijinga, JK; Breimer, DD; Danhof, M; van Zuilen, A, 1982
)
0.75
" After sulfamerazine was given orally, there was a marked evolution in the shape of the concentration-time curves in function of age, strongly suggesting a defective absorption rate in the first weeks after birth."( Pharmacokinetics of sulfamerazine and antipyrine in neonatal and young lambs.
Belpaire, FM; Bogaert, MG; De Backer, P; Debackere, M, 1982
)
0.54
" In vivo drug metabolism as estimated by the plasma elimination rate of orally-administered antipyrine was not significantly affected by this treatment although there was an apparent decrease in the absorption rate of the drug."( The effect of isolation stress on some hepatic drug and carcinogen metabolising enzymes in rats.
Capel, ID; Dorrell, HM; Jenner, M; Pinnock, MH; Williams, DC, 1980
)
0.48
" Absolute bioavailability of an aqueous solution of antipyrine was on average 97%."( Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
Eichelbaum, M; Ochs, HR; Roberts, G; Somogyi, A, 1982
)
0.79
" The method was designed to study the bioavailability of different commercial tablets from salivary concentration data."( Rapid thin-layer chromatography of various weak analgesics in saliva.
Drehsen, G; Rohdewald, P, 1981
)
0.26
" Also there is no evidence as yet, that patients with liver disease and without a collateral portal circulation do have an increased bioavailability of oral high clearance drugs."( [Drug metabolism in patients with liver disease (author's transl)].
Epping, J; Fuchshofen-Röckel, M; Heusler, H; Richter, E; Zilly, W, 1980
)
0.26
" The rate of absorption of antipyrine was moderately decreased by methotrexate."( The effect of antineoplastic drugs on the pharmacokinetics of antipyrine in the rat.
Aarbakke, J; Høyem-Johansen, T; Høylandskjaer, A; Slørdal, L, 1980
)
0.8
"The bioavailability of the four metabolites of metamizole (CAS 68-89-3), 4-methyl-amino-antipyrine (4-MAA), 4-formyl-amino-antipyrine (4-FAA), 4-amino-antipyrine (4-AA) and 4-acetyl-amino-antipyrine (4-AcAA) was compared after oral administration of a test (Analgin) and a reference formulation, both containing 1 g of metamizole."( Comparative bioavailability of two oral metamizole formulations. Influence of the acetylation phenotype.
Bacracheva, N; Drenska, A; Gorantcheva, J; Tyutyulkova, N; Vlahov, V, 1995
)
0.51
" The relative bioavailability of the capsule formulation of antipyrine was 97%."( Antipyrine repeatability and comparison of the powder and capsule formulations.
Edeki, T; Turner, P, 1995
)
1.98
"05) instead of decreased as one would expect because of enzyme induction, presumably due to a decrease in systemic bioavailability and its influence on the oral volume of distribution."( Enzyme induction by moricizine: time course and extent in healthy subjects.
Benedek, IH; Davidson, AF; Pieniaszek, HJ, 1994
)
0.29
" In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively."( Assessment of drug exposure in rat dietary studies.
Bazot, D; Brillanceau, MH; Jochemsen, R; Lupart, M, 1993
)
0.48
" The extent of bioavailability remained unchanged."( Effects of nocloprost (9 beta-chloro-16,16-dimethyl PG E2) on absorption and disposition of antipyrine and sulfamethazine in healthy volunteers.
Amon, I; Franke, G; Müller, C; Siegmund, W; Zschiesche, M, 1993
)
0.51
"The objective of the study was to investigate the effects of hepatic impairment on the absolute transnasal bioavailability and pharmacokinetics of butorphanol."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
" The absolute transnasal bioavailability of butorphanol was significantly higher (approximately 20%) in patients with hepatic impairment."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
" It is suggested that the potentiated local anaesthetic effect of the combination may be partly due to enhanced local bioavailability of lidocaine."( Phenazone potentiates the local anaesthetic effect of lidocaine in mice.
Gillardin, JM; Heulard, I; Verleye, M, 2000
)
0.31
" Papp of IDM was greater than that of TAT, indicating that the order corresponded with that of in vivo bioavailability after oral administration of their PEG 600 solutions."( Evaluation of absorbability of poorly water-soluble drugs: validity of the use of additives.
Hayashi, M; Sudo, R; Takahashi, M; Watanabe, E, 2000
)
0.31
" The new methodology may, therefore, be used for fast bioavailability screening of virtual libraries having millions of molecules."( Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Ertl, P; Rohde, B; Selzer, P, 2000
)
0.31
" Furthermore, oral bioavailability values were equal to or lower than hepatic availability values predicted from the serum incubation method."( A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum.
Ishii, Y; Shibata, Y; Takahashi, H, 2000
)
0.31
" NT also facilitated transcellular uptake of (3)H-glucose and (3)H-leucine and increased paracellular uptake to (51)Cr-EDTA and (3)H-mannitol, but did not alter the absorption rate for (14)C-antipyrine."( Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats.
Carraway, RE; Gui, X, 2001
)
0.5
"The effects of hepatic and presystemic enzyme induction on the bioavailability (F) and disposition of antipyrine after repeated rifampicin (RFM) and rifabutin (RBT) exposure were studied in mice."( Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.
Li, RC; Liu, XG; Narang, PK,
)
0.6
"The purpose of this study was to develop and validate a method for separately evaluating the roles of gastrointestinal absorption and hepatic extraction as barriers to oral bioavailability (BA)."( Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
Aungst, B; Dobson, G; Hidalgo, I; Letendre, L; Scott, M, 2004
)
0.32
" Pharmacokinetic parameters including bioavailability were calculated for each compound for each route of administration."( Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
Aungst, B; Dobson, G; Hidalgo, I; Letendre, L; Scott, M, 2004
)
0.32
" Antipyrine was highly bioavailable by all routes."( Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
Aungst, B; Dobson, G; Hidalgo, I; Letendre, L; Scott, M, 2004
)
1.23
" This increase was paralleled by increases in the absorption rate constant AUC and antipyrine bioavailability."( Membrane permeability and antipyrine absorption in a rat model of ischemic colitis.
Ishitobi, Y; Kawashima, S; Koga, K; Murakami, M; Taniguchi, M, 2004
)
0.85
" The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively."( Excipient effects on gastrointestinal transit and drug absorption in beagle dogs.
Basit, AW; Coffin, MD; Parsons, GE; Peters, EE; Schulze, JD; Staton, JS; Vickers, AW, 2005
)
0.53
" Topotecan, an anti-cancer drug widely used in metastatic carcinoma, is a P-glycoprotein substrate having oral bioavailability of 30% with large inter-patient variability."( Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies.
Bansal, T; Jaggi, M; Khar, RK; Mishra, G; Mukherjee, R; Singh, M; Talegaonkar, S, 2007
)
0.57
"To clarify the causes of low oral bioavailability (BA) of drugs in cynomolgus monkeys, the experimental method to evaluate the drug permeability and the metabolism in the intestine of cynomolgus monkeys was established."( Investigation of the intestinal permeability and first-pass metabolism of drugs in cynomolgus monkeys using single-pass intestinal perfusion.
Igeta, K; Suzuki, N; Takahashi, M; Washio, T; Yamashita, S, 2010
)
0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" On the other hand, bioavailability of oral mucosal, rectal and oral administration was about 100, 63."( A novel administration route of edaravone--II: mucosal absorption of edaravone from edaravone/hydroxypropyl-beta-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite.
Ishii, F; Mizuno, K; Sato, T, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
"The rate of absorption at 15 min was calculated to be 13."( Relationship between lipophilicity and absorption from the liver surface of paraben derivatives and antipyrine in rats.
Fumoto, S; Kobayashi, M; Miyamoto, H; Nakamura, J; Nishida, K; Sasaki, H; Yoshikawa, N, 2011
)
0.59
"The rate of absorption of a drug from the liver surface could be estimated from physicochemical properties such as lipophilicity and molecular weight."( Relationship between lipophilicity and absorption from the liver surface of paraben derivatives and antipyrine in rats.
Fumoto, S; Kobayashi, M; Miyamoto, H; Nakamura, J; Nishida, K; Sasaki, H; Yoshikawa, N, 2011
)
0.59
" We have probably wasted too much time on agents like antioxidant vitamins instead of focusing on more disease specific, target-directed, highly bioavailable antioxidants."( Antioxidant therapy: current status and future prospects.
Firuzi, O; Miri, R; Saso, L; Tavakkoli, M, 2011
)
0.37
"To understand the rate-limiting process of oral drug absorption, not only total bioavailability (F) but also intestinal (F(a) · F(g)) and hepatic (F(h)) availability after oral administration should be evaluated."( Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats.
Kobayashi, T; Konno, Y; Matsuda, Y; Morisaki, K; Satsukawa, M; Takimoto, Y; Yamashita, S, 2012
)
0.38
"These results support the critical role of NO in the microcirculation and suggest that free-radical scavenging increases the bioavailability of NO in the microcirculation via eNOS upregulation."( Effect of a free radical scavenger on nitric oxide release in microvessels.
Sakamoto, K; Totani, N; Yamamoto, J; Yamanishi, H; Yamashita, T, 2013
)
0.39
"The objective of the study was to evaluate the effect of hydroxypropyl-sulfobutyl-β-cyclodextrin (HP-SBE-βCD) on the bioavailability and intestinal absorption of edaravone, and identify its mechanism of action."( Hydroxypropyl-sulfobutyl-β-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes.
Guo, M; Lu, Y; Lu, YP; Ren, Y; Rong, WT; Tao, Q; Yu, SQ, 2014
)
0.4
" Most importantly, 3d possessed a very high absolute bioavailability and was rapidly distributed in brain tissue to keep high plasma drug concentration for the treatment of ischemic strokes."( Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent.
Lan, Z; Lei, M; Li, J; Liang, Z; Xu, W; Xu, X; Zhang, X; Zhao, C, 2015
)
0.42
" These activities, associated to a good predictive bioavailability and a lack of cytotoxicity, design it as a promising hit for further in vivo investigation."( Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment.
Corvaisier, S; Cresteil, T; Dallemagne, P; El Kihel, L; Jourdan, JP; Lecoutey, C; Legay, R; Malzert-Fréon, A; Rochais, C; Since, M; Sopkova-de Oliveira Santos, J, 2016
)
0.43
"Edaravone (EDR), a strong free radical scavenger, is known for its promising therapeutic potential in oxidative stress (OS) associated diseases, however poor oral bioavailability is the major obstacle in its potential use."( Development of a novel oral delivery system of edaravone for enhancing bioavailability.
Garg, S; Kathawala, K; Parikh, A; Tan, CC; Zhou, XF, 2016
)
0.43
" However, its oral use is restricted due to poor oral bioavailability (BA)."( Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation.
Garg, S; Kathawala, K; Parikh, A; Tan, CC; Zhou, XF, 2017
)
0.46
" Pharmacokinetic experiments performed with rats and beagles showed that the absolute bioavailability of EDR solution and enteric-coated pellets following oral administration were 33."( Gastric retention pellets of edaravone with enhanced oral bioavailability: Absorption mechanism, development, and in vitro/in vivo evaluation.
Cheng, Y; Guan, S; Hu, M; Huang, W; Li, Q; Mo, J; Ou, Z; Wang, J; Yang, J; Zhang, ZJ, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Highly bioavailable form of novel edaravone formulation developed using self-nanomicellizing solid dispersion strategy which showed up to 16."( Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats.
Luo, HY; Parikh, A; Xiong, YX; Ye, QY; Zhao, LQ; Zhou, XF, 2022
)
0.72
"Higher levels of 5-HT in brain, plasma and small intestines were recognized in 5-HT-excessive rats, where the oral bioavailability of CEX was significantly enhanced."( Effect of Excessive Serotonin on Pharmacokinetics of Cephalexin after Oral Administration: Studies with Serotonin-Excessive Model Rats.
Higaki, K; Iwamoto, T; Maruyama, M; Nakashima, S; Ogawara, KI; Takanashi, M, 2022
)
0.72
"5-HT-excessive condition enhanced the oral bioavailability of CEX in rats, which would be attributed to the enhanced permeability across the intestinal mucosa via passive diffusion through the paracellular route even though the transport via PEPT1 was decreased."( Effect of Excessive Serotonin on Pharmacokinetics of Cephalexin after Oral Administration: Studies with Serotonin-Excessive Model Rats.
Higaki, K; Iwamoto, T; Maruyama, M; Nakashima, S; Ogawara, KI; Takanashi, M, 2022
)
0.72

Dosage Studied

Antipyrine is a marker of microsomal oxidative metabolism. The potential of antipyrine phenotyping for individualisation of anesthetics' dosing is discussed.

ExcerptRelevanceReference
" Salicylamide, an analgesic without effect on the prostaglandin synthesis was in the oral exposition test of 18 patients with proved analgesics-asthma-syndrome in the dosage of 500 mg subjectively and objectively tolerated without reaction."( [Salicylamide-- a potential pain-remedy alternative in the analgesic asthma syndrome].
Hummel, S; Jäger, L; Slapke, J, 1979
)
0.26
" MPA dosage was 250 mg, intramuscularly, for 6 days."( Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.
Kauppila, AJ; Rautio, A; Sotaniemi, EA; Tuimala, RJ, 1979
)
1.7
" After dosage with phenazone, 4,4'-dihydroxyphenazone is excreted in conjugated form by man, rabbit, guinea pig and rat."( 4,4'-Dihydroxyphenazone as an urinary metabolite of phenazone in different species including man.
Bässmann, H; Böttcher, J; Schüppel, R, 1979
)
0.26
" The influence of variation in the pharmaceutical dosage form on the pharmacokinetic behaviour patterns of phenazone were studied and intraindividual differences not inconsiderable are obvious."( [On the pharmacokinetics of phenazone in man (author's transl)].
Brinkmann, HJ; Hengstmann, JH; Müller, F, 1977
)
0.26
" These data do not provide pharmacokinetic support for a general reduction of the Doleron dosage in elderly subjects."( Absorption and elimination of D-propoxyphene, acetyl salicylic acid, and phenazone in a combination tablet (Doleron): comparison between young and elderly subjects.
Bodin, NO; Danielson, K; Gustafsson, B; Haglund, G; Melander, A; Westerlund, D, 1978
)
0.26
" It is concluded that both decreased liver mass and decreased hepatic enzyme activity contribute to the impairment of drug oxidation which occurs in the elderly and which may warrant a reduction in dosage of some drugs."( Antipyrine disposition and liver size in the elderly.
Halliwell, M; Homeida, M; Roberts, CJ; Swift, CG, 1978
)
1.7
" As a consequence, shorter dosing intervals of these drugs seems to be advisable, rather than a reduction in the total daily dose."( Drug protein binding and the nephrotic syndrome.
Azarnoff, DL; Gugler, R, 1976
)
0.26
" The pharmacokinetic characteristics of a drug as well as the severity of liver disease should be taken into account when considering drug dosage in patients with chronic liver disease."( Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
Adjepon-Yamoah, KK; Finlayson, ND; Forrest, JA; Prescott, LF, 1977
)
1.7
" The pharmacokinetics of ticlopidine, a novel antithrombotic agent, have been investigated in 10 healthy volunteers dosed orally with the drug (250 mg 12 hourly for 21 days), to determine the basic pharmacokinetic parameters in humans, to investigate its accumulation during repeated administration, and to assess its effects on hepatic drug-metabolizing enzymes."( Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics.
Allen, JG; Bastain, W; Dickinson, JP; Knudsen, JB; Sefton, CM, 1992
)
0.5
" Unknown additional peaks were detected in urine after NORA dosing but not after HMA or OHA administration."( The pharmacokinetics of antipyrine and three of its metabolites in the rabbit: intravenous administration of pure metabolites.
Abul-Hajj, Y; Awni, WM; St Peter, JV, 1991
)
0.59
" Furthermore the antipyrine dosage can be minimized, because of the sensitivity of the HPLC-method."( The determination of antipyrine elimination in saliva by liquid chromatography.
Gartzke, J; Jäger, H, 1991
)
0.94
"To determine whether natural human interferon administered under the usual therapeutic dosing scheme would inhibit the hepatic drug metabolism, we performed an antipyrine test in eight patients with chronic B or non-A, non-B hepatitis before and after a subchronic interferon therapy (6 megaunits/day for 17 +/- 4 days, mean +/- SD)."( Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis.
Echizen, H; Ishizaki, T; Oda, T; Ohta, Y; Shirataki, H; Tsukamoto, K; Umeda, N, 1990
)
0.71
" The trial was open, randomized, and cross-over, with a one-week interval between dosing days."( Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium.
Bacracheva, N; Badian, M; Verho, M; Vlahov, V, 1990
)
0.28
"1 mM) or on the rate of N-demethylation of aminopyrine or O-dealkylation of Ec in microsomes produced from rats dosed chronically with Hf (200 mg/kg) for 4 days."( Lack of effect of halofantrine on hepatic drug metabolism in the rat in vivo and in vitro.
Edwards, G; Hoaksey, PE; Milton, KA; Ward, SA, 1990
)
0.28
" Blood samples for the determination of ciprofloxacin concentrations were taken at 0, 1, 2, 4, 6, and 12 hr after dosing on the first and seventh day of drug administration."( Metabolic interactions of ciprofloxacin.
Csiba, A; Graber, H; Ludwig, E; Székely, E,
)
0.13
" A graded dose-response relationship was found between PB treatment and most but not all parameters."( Drug metabolizing capacity in vitro and in vivo--II. Correlations between hepatic microsomal monooxygenase markers in phenobarbital-induced rats.
Houston, JB; Matthew, DE, 1990
)
0.28
" Analysis of the concentration-time curve for antipyrine after simultaneous dosing and start of the 23% regimen suggests that the increase in metabolic capacity occurred within a few hours."( Effects of parenteral amino acid nutritional regimens on oxidative and conjugative drug metabolism.
Lee, YJ; Pantuck, CB; Pantuck, EJ; Weissman, C, 1989
)
0.54
" After 2 weeks' treatment, CBZ daytime levels measured as area under the concentration-time curve over a dosage interval were 7% lower with CBZ-CR, but this difference was not statistically significant."( A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.
Brodie, MJ; Butler, E; Larkin, JG; McLellan, A; Munday, A; Sutherland, M, 1989
)
0.28
" However, on a pharmacokinetic basis a reduced dosage of midazolam to patients with advanced cirrhosis of the liver is recommended."( Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
Crevoisier, C; Himberg, JJ; Pentikäinen, PJ; Välisalmi, L, 1989
)
0.28
" The metabolic disposition of antipyrine (AP) and m-xylene (XYL) has been studied in rats pretreated for a prolonged period with XYL, dosed alone or in combination with ethanol, phenobarbital (PB), or 3-methylcholanthrene (MC)."( Metabolism of antipyrine and m-xylene in rats after prolonged pretreatment with xylene alone or xylene with ethanol, phenobarbital or 3-methylcholanthrene.
Aitio, A; Elovaara, E; Engström, K; Hase, T; Häyri, L, 1989
)
0.93
"During a multiple dosing regimen, the area under the promethazine blood concentration-time profile progressively decreased indicating auto-induction of metabolism."( Changes in the disposition of promethazine during multiple dosing in the rabbit.
Houston, JB; Taylor, G, 1985
)
0.27
" Rifampin kinetics were measured at the end of the 22-day dosing period."( The kinetics of induction by rifampin of alpha 1-acid glycoprotein and antipyrine clearance in the dog.
Abramson, FP; Lutz, MP,
)
0.36
" Elimination of these model drugs was studied before and during 8 days of famotidine dosing in 8 healthy volunteers."( Effect of famotidine on oxidative drug metabolism.
Kitchingman, GA; Langman, MJ; Somerville, KW, 1986
)
0.27
" Rats were partially exchanged with Fluosol-DA and dosed with antipyrine at selected time intervals following exchange."( Antipyrine kinetics following partial blood exchange with Fluosol-DA in the rat.
Pollack, GM; Shrewsbury, RP; Wargin, WA; White, SG, 1986
)
1.95
" The pharmacokinetics of antipyrine were assessed in eight male normal subjects after single oral doses of 10 mg/kg antipyrine, administered prior to chronic dosing with temelastine 100 mg twice daily for 2 weeks, and 48 hours after the last dose of temelastine."( Temelastine, a novel histamine H1-receptor antagonist, does not induce oxidative hepatic enzyme activity in man.
de Mey, C; Meineke, I; Wesche, H,
)
0.43
" In the same subjects, rifabutin in the proposed therapeutic dosage (300 mg daily) for 7 days also enhanced the metabolic elimination of antipyrine, with preferential stimulation of the demethylation pathway, and increased the excretion of 6-beta-hydroxycortisol, but the magnitude of the effects was significantly less than after rifampicin."( Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.
Frigo, GM; Grimaldi, R; Mönig, H; Ohnhaus, EE; Perucca, E; Sardi, A, 1988
)
0.48
" The plasma concentrations of propranolol under these steady state dosing conditions increased when misoprostol was added to propranolol."( Potential drug interactions with misoprostol: effects on the pharmacokinetics of antipyrine and propranolol.
Bennett, PN; Fenn, GC; Notarianni, LJ, 1988
)
0.5
" Hepatic biotransformation capability before flecainide dosing was assessed by antipyrine challenge."( Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
Chang, SF; Conard, GJ; McQuinn, RL; Pentikäinen, PJ, 1988
)
0.5
" The dosage of ciprofloxacin was 500 mg bd by mouth for 8-10 days."( The effect of ciprofloxacin on antipyrine metabolism.
Csiba, A; Graber, H; Ludwig, E; Székely, E, 1988
)
0.56
" The severe impairment of hepatic mixed function oxidase activity even in the symptomless stage of porphyria indicates cautious dosage of drugs primarily eliminated by hepatic oxidative reactions."( Haem arginate improves hepatic oxidative metabolism in variegate porphyria.
Himberg, JJ; Mustajoki, P; Tokola, O, 1988
)
0.27
" On the other hand despite a relatively highly dosed one-week treatment propyphenazone did not lead to changes of the demethylation capacity of the liver in the majority of the patients."( [Effect of propyphenazone on drug biotransformation in the liver. A comparison with phenylbutazone using the aminopyrine breath test].
Clemens, M; Reinicke, C; Steiner, A; Stiller, KJ; Tanner, E; Wächter, G, 1988
)
0.27
" After oral dosage in the fasting state, young and elderly groups (regardless of gender) did not differ in peak plasma antipyrine concentration (Cmax) or time of peak concentration (Tmax)."( Antipyrine absorption and disposition in the elderly.
Divoll, MK; Greenblatt, DJ; Harmatz, JS; Shader, RI, 1988
)
1.93
") or repeated clonidine dosing (0."( Clonidine effects on disposition of xenobiotics in rats: inhibited elimination of flow-limited but not extraction-limited agents.
Ben-Zvi, Z; Hurwitz, A, 1988
)
0.27
" At the end of this period, P was continued at the same dosage but F (300 mg daily) was added and both drugs were given simultaneously for a further eight-day period (period P + F)."( Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate.
Desager, JP; Harvengt, C; Heller, FR, 1988
)
0.27
" Rapid irreversible inhibition occurred in some cases, and this could be responsible for in vivo inhibition after repeated dosing of these MAOIs."( Inhibition of cytochrome P-450-dependent oxidation reactions by MAO inhibitors in rat liver microsomes.
Davies, DS; Dupont, H; Strolin-Benedetti, M, 1987
)
0.27
" Antipyrine concentrations in saliva after oral dosing were measured by HPLC."( Antipyrine kinetics in liver disease and liver transplantation.
Burckart, GJ; Gray, JA; Mehta, MU; Ptachcinski, RJ; Starzl, TE; Van Thiel, DH; Venkataramanan, R; Yang, SL, 1986
)
2.62
" Differences in CBZ and CBZ-E disposition between day and night dosing were minor."( Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism.
Brodie, MJ; Butler, E; Macphee, GJ,
)
0.13
" 5 The findings suggest that there is a selective impairment of N-demethylation in the elderly which may have important implications for dosage of elderly patients with drugs metabolised by this route."( The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.
Breimer, DD; Danhof, M; Posner, J; Teunissen, MW; Whiteman, PD, 1987
)
0.6
" Antipyrine pharmacokinetics were studied immediately before midazolam administration was started, after the dosage schedule had been completed and one week after dosing had been discontinued."( The effect of midazolam (Hypnovel) administration on antipyrine pharmacokinetics in humans.
Alderson, J; Allen, JG; Galloway, DB; Hallett, C, 1987
)
1.43
" The lack of any clinically significant effect of smoking withdrawal on hepatic blood flow or on the disposition of antipyrine, a drug with very low hepatic extraction, indicates that on a pharmacokinetic basis, changes in dosage regimens for most drugs are not necessary on acute withdrawal from smoking."( The effect of acute withdrawal from cigarette smoking on indocyanine green and antipyrine clearance.
Eldon, MA; Luecker, PW; MacGee, J; Ritschel, WA, 1987
)
0.71
" Thus, on a pharmacokinetic basis the loading dose of mexiletine need not be modified in cirrhotic patients, whereas the maintenance dosage should be reduced to one fourth - one third of the usual dose."( Cirrhosis of the liver markedly impairs the elimination of mexiletine.
Halinen, MO; Hietakorpi, S; Lampinen, LM; Pentikäinen, PJ, 1986
)
0.27
" Aminophenazone suppositories of an equivalent dosage led to significant higher values of plasma concentrations if compared with propyphenazone."( [Availability of propylphenazone from suppositories. 2. Bioavailability].
Bornschein, M; Dietzsch, B; Gabrio, T; Grune, D; Hackenberger, F; Voigt, R, 1986
)
0.27
"Plasma levels of N-carboxy-3-morpholinosydnonimine ethyl ester (molsidomine, Corvaton) and its pharmacologically active metabolite 3-morpholinosydnonimine (SIN-1) were measured in six healthy male and female volunteers after single intravenous and oral dosing of 4 mg molsidomine."( Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
Chamberlain, J; Gärtner, W; Ostrowski, J; Stockhausen, H; Wildgrube, HJ, 1986
)
0.27
" Verapamil elimination was also found to be impaired after chronic dosing as compared to single administration."( The effect of oral verapamil therapy on antipyrine clearance.
Kokurina, EV; Metelitsa, VI; Piotrovskii, VK; Riabokon, OS; Rumiantsev, DO; Slastnikova, ID, 1986
)
0.54
" Mefloquine (750 mg) had no significant effect on salivary kinetics of antipyrine or on the metabolic clearance of antipyrine to its three main metabolites, 3-hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine, when antipyrine was administered either 2 h or 2 weeks after dosing with mefloquine."( The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
Back, DJ; Breckenridge, AM; Howells, RE; Rivière, JH, 1985
)
0.73
" When data before metronidazole dosing were compared with those after metronidazole dosing, there were no changes in total plasma clearance of diazepam (0."( Interaction between metronidazole and drugs eliminated by oxidative metabolism.
Gugler, R; Jensen, JC, 1985
)
0.27
" A significant increase of the liberation rate of propyphenazone (re-crystallized from various media) has been realized by direct pressing of polyvinylpolypyrrolidone and Heweten 40 as well as by gelatine solution granulation, with which the last method exhibits the advantage of an increased accuracy of dosage and a decreased friability."( [The increase in the liberation rate of propyphenazone from preoral solid dosage forms].
Götte, M; Thomas, G; Voigt, R, 1985
)
0.27
" Dose-response curves were constructed for five agents."( The effectiveness of local injections of vasodilating agents to produce vasodilation in subcutaneous tissue in rabbits.
DeYoung, NJ; Duncan, HJ; Faris, IB, 1985
)
0.27
"Antipyrine total clearance and the formation clearance of its major metabolites were studied in normal, healthy male volunteers before and after multiple dosing for approximately three weeks with phenytoin (six subjects) and carbamazepine (six subjects)."( Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
Hopkins, K; Houston, JB; Morselli, PL; Rowland, M; Shaw, PN; Thiercelin, JF, 1985
)
3.15
" The results suggest that the dosage of mexiletine should be adjusted when enzyme inducing drugs are started or stopped during therapy with it."( Effect of rifampicin treatment on the kinetics of mexiletine.
Hiltunen, HA; Koivula, IH; Pentikäinen, PJ, 1982
)
0.26
" Thus, it appears that trauma may have a significant, and possibly selective, effect on hepatic drug metabolism, suggesting that careful monitoring and/or dosage adjustment may be in order in some cases of post-traumatic drug therapy."( Effects of model traumatic injury on hepatic drug metabolism in the rat. I. In vivo antipyrine metabolism.
Griffeth, LK; Rauckman, EJ; Rosen, GM; Tschanz, C,
)
0.36
" The reduction in steady-state beta-adrenergic receptor drug concentration following enzyme induction is sufficiently large that an altered pharmacodynamic response would be expected if no dosage modification is made."( Enzyme induction and beta-adrenergic receptor blocking drugs.
Branch, RA; Herman, RJ, 1984
)
0.27
" Antipyrine pharmacokinetics were studied immediately before bromazepam administration was started, after the dosing schedule had been completed and one week after dosing had been discontinued."( The effect of bromazepam (Lexotan) administration on antipyrine pharmacokinetics in humans.
Allen, JG; Bird, HA; Ehsanullah, RS; Galloway, DB; Ruane, RJ, 1984
)
1.43
" It has been useful as a research tool in identifying environmental factors for which dose-response curves can be generated and compared."( Assessment of methods to identify sources of interindividual pharmacokinetic variations.
Penno, MB; Vesell, ES,
)
0.13
" The knowledge of pharmacokinetics give essential informations for the development of new pharmaceutical forms, adjustment of dosage regimen and recommendations for drug intake in order to minimize the variations in bioavailability and to improve compliance."( [Pharmacokinetics: a contribution in clinical geriatric pharmacology?].
Humbert, H; Kiechel, JR; Lavène, D, 1983
)
0.27
" The aim of our studies on patients with various chronic liver diseases was to get information about the rational dosage for these patients."( Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
Horváth, T; Jávor, T; Kádas, I; Pár, A; Past, T; Tapsonyi, Z; Tatai, Z,
)
0.13
" Significant positive correlations were found between the dosage of CBZ, DPH, PMD and PB and both indices of enzyme induction."( A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.
Hedges, A; Makki, KA; Perucca, E; Richens, A; Ruprah, M; Wilson, JF, 1984
)
0.27
" Thus, the drug-metabolizing capacity in diabetics seems to be markedly reduced, and drug dosage might have to take account of this fact."( [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
Dennin, DE; Oltmanns, D; Pentz, R; Siegers, CP, 1984
)
1.18
" The results have been evaluated from the methodological aspect to work out an appropriate dosage regime in liver diseases."( Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Beró, T; Fábián, C; Horváth, T; Jávor, T; Kádas, I; Pár, A, 1983
)
0.27
" This dosage also induces the first and the second phases of reactions."( Human tolerance of flumecinol (Zixoryn, RGH-3332), its regime and dosage in healthy volunteers.
Ferenci, J; Horvath, T; Jávor, T; Nagy, L; Past, T; Radnai, B; Vezekenyi, Z, 1983
)
0.27
"The authors studied antipyrine disposition before and after delivery in 4 epileptic women whose anticonvulsant plasma level per dosage ratio was lowered during pregnancy, and compared the results to those found in nonpregnant women undergoing antiepileptic treatment (N = 6) and healthy women (N = 6)."( Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy.
Chiba, K; Ishizaki, T; Nakazawa, Y; Tabuchi, T; Wagatsuma, T, 1982
)
2.03
" This allows for various dosing regimens."( A rapid gas-liquid chromatographic determination of antipyrine clearance in the rat.
Adams, JF; Cousins, MJ; Gourlay, GK; Knights, KM, 1981
)
0.51
" The variable nature of the changes precludes any uniform prediction about growth hormone effects on drug metabolism, but it may be necessary in some children to modify the dosage of other drugs administered with hGH."( Effects of growth hormone on antipyrine kinetics in children.
Levine, LS; New, MI; Pareira, J; Rifkind, AB; Saenger, P, 1981
)
0.55
" 2 Antipyrine elimination was slightly but significantly slowed by 28 days treatment with phenelzine but the degree of slowing was uninfluenced by acetylator phenotype or dosage of phenelzine administered."( Antipyrine elimination by patients under treatment with monoamine oxidase inhibitors.
Lambourn, J; Smith, SE; Tyrer, PJ, 1980
)
2.33
" Before oral dosing a complete emptying of the rat stomach was obtained by 24 hours of fasting and prevention of coprophagy."( The effect of antineoplastic drugs on the pharmacokinetics of antipyrine in the rat.
Aarbakke, J; Høyem-Johansen, T; Høylandskjaer, A; Slørdal, L, 1980
)
0.5
" dosing groups after 3 and 7 days of simulated weightlessness."( Antipyrine pharmacokinetics in the tail-suspended rat model.
Brunner, LJ; DiPiro, JT; Feldman, S, 1995
)
1.73
" The use of caffeine containing drugs in obese subjects does not necessitate significant dosage modification."( Caffeine pharmacokinetics in obesity and following significant weight reduction.
Berry, EM; Caraco, Y; Levy, M; Zylber-Katz, E, 1995
)
0.29
" We conclude that the moricizine dose required for arrhythmia patients with hepatic disease should be lower, and perhaps, the dosing frequency should be less than in patients with normal liver function."( The effect of hepatic disease on the disposition of moricizine in humans.
Davidson, AF; Mayersohn, M; McEntegart, CM; Pieniaszek, HJ; Quon, CY; Sampliner, RE, 1994
)
0.29
" Antipyrine plasma concentrations were measured without pantoprazole (day 1), on the last day of chronic dosing with pantoprazole (day 12) and 48 hours after the last dose of pantoprazole (day 14) to differentiate between inhibition and induction, respectively."( Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
Bliesath, H; De Mey, C; Hartmann, M; Huber, R; Meineke, I; Steinijans, VW; Wurst, W, 1994
)
1.47
" In a third infusion, the dams alone received a higher dosage of dideoxyinosine (425 micrograms/min/kg) and the same dosage of antipyrine (41."( Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques.
Baughman, WL; Nosbisch, C; Pereira, CM; Unadkat, JD; Winter, HR, 1994
)
0.49
" Long-term survivors deserve monitoring of liver function for safer methotrexate use, in the light of progressive dosage increments to improve prognosis in neoplastic diseases."( High-dose methotrexate treatment and liver function in patients with osteosarcoma.
Bacci, G; Fabbri, A; Ferrari, S; Figus, E; Longhi, C; Marchesini, G; Marchi, E; Motta, E, 1994
)
0.29
" In patients, linear and dose-proportional kinetics with no autoinduction of metabolism simplify OCBZ dosage adjustment."( Clinical pharmacology and pharmacokinetics of oxcarbazepine.
Dieterle, W; Flesch, G; Lloyd, P, 1994
)
0.29
"Many drugs eliminated by the liver exhibit age-related differences in systemic clearance, necessitating different dosage requirements in children and adults."( Liver volume as a determinant of drug clearance in children and adolescents.
Bhargava, R; Crom, WR; Evans, WE; Murry, DJ; Reddick, WE, 1995
)
0.29
" The statistically significant changes were small in absolute terms and showed no dose-response relationship."( Absence of hepatic enzyme induction in prostate cancer patients receiving 'Casodex' (bicalutamide).
Kaisary, A; Klarskov, P; McKillop, D, 1996
)
0.29
" Antipyrine plasma concentrations were measured without pantoprazole (day 1), on the last day of chronic dosing with pantoprazole (day 12) and 48 hours after the last dose of pantoprazole (day 14) to differentiate between inhibition and induction, respectively."( Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
Bliesath, H; De Mey, C; Hartmann, M; Huber, R; Meineke, I; Steinijans, VW; Wurst, W, 1996
)
1.48
" Nonetheless, GHB plasma concentrations fell to either undetectable or negligible levels by the end of the usual dosing intervals (6-8 h)."( Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
Ferrara, SD; Frison, G; Mazzo, M; Orlando, R; Padrini, R; Palatini, P; Tedeschi, L; Zordan, R, 1996
)
0.29
" However, the subsequent dosing intervals for butorphanol should be prolonged."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
" However, because nalmefene will be primarily used in the acute care setting for reversal of opioid-induced effects, it is not likely that these alterations will necessitate a dosage modification."( Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Dixon, R; Frye, RF; Matzke, GR; Rabinovitz, M; Schade, R, 1997
)
0.3
" Plasma antipyrine concentrations during 24 to 48 hours after dosage were measured by high-performance liquid chromatography."( Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics.
Abernethy, DR; Greenblatt, DJ; Harmatz, JS; Luna, BG; Scavone, JM; Shader, RI, 1997
)
0.96
" dosing is more likely to produce levels at which bone marrow toxicity occurs."( Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever.
Acharya, GP; Acharya, S; Chataut, C; Dance, DA; Davis, TM; Harris, S; Ho, M; Kafle, KE; Nosten, F; Pokhrel, B; Smith, A; Tuhladar, N; Weber, A; White, NJ, 1997
)
0.3
" It points to the effect of estrogens on the metabolism of medicaments in the liver and indicates a careful dosage of some medicines in chronic use which have a long biological half-life in post-menopausal women and in women following surgical ovariectomy."( [The effect of ovariectomy in women on metabolism of phenazone].
Konieczny, M, 1996
)
0.29
" It should be taken into account when dosing drugs which are metabolized as markers of the liver metabolic efficiency like phenazone and sulphadimidine."( [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
Kotlarek-Haus, S; Milejski, P; Orzechowska-Juzwenko, K; Urbaniak-Kujda, D; Usnarska-Zubkiewicz, L; Wiela-Hojeńska, A, 1997
)
0.3
" If replicated in humans, these substantial age-dependent changes in the pharmacokinetics of zalcitabine would warrant smaller and less frequent dosing with zalcitabine in HIV-infected neonates than in older children and adults."( Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina).
Nosbisch, C; Tuntland, T; Unadkat, JD, 1997
)
0.3
"Pharmacokinetic analysis suggests a longer dosage interval may be appropriate in patients with hepatic impairment."( Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
Adams, MH; Ferry, JJ; Garnett, WR; Karnes, HT; Poynor, WJ; Ryan, KK; Sarkar, MA, 1998
)
0.3
" Our results demonstrate that the HSN tumour vasculature is selectively responsive to IRL 1620 at doses > 1 nmol kg(-1) compared with the majority of normal tissues with the exception of the small intestine, and that only the tumour response is highly sensitive to BQ-788 antagonism, under the experimental dosing regime investigated."( Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620.
Bell, KM; Chaplin, DJ; Poole, BA; Prise, VE; Tozer, GM, 1999
)
0.3
" It should be considered in individualization of their dosage regimen."( Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
Hurkacz, M; Kotlarek-Haus, S; Orzechowska-Juzwenko, K; Usnarska-Zubkiewicz, L; Wiela-Hojenska, A, 1999
)
0.3
" Also, the specific parameters for oral solid dosage forms were determined."( Oral lyophilizate--an alternative for products with low-soluble drugs.
Cojocaru, I; Drăgănoiu, S; Gafiţeanu, E,
)
0.13
" [C-Methyl-(13)C]antipyrine (500 mg) was dosed orally to human volunteers, and the post-dose urine was analyzed by 100-MHz (13)C NMR spectroscopy under the conditions of distortionless enhancement by polarization transfer (DEPT) without any pretreatments such as deconjugation, chromatographic separation, or solvent extraction."( Direct nuclear magnetic resonance spectroscopic analysis of (13)C-labeled antipyrine metabolites in human urine.
Akira, K; Hashimoto, T; Imachi, M; Negishi, E, 2001
)
0.88
" ICR mice were divided to receive 4 daily oral dosing of either the dosing vehicle or 50 mg/kg of REM or RBT."( Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.
Li, RC; Liu, XG; Narang, PK,
)
0.38
" Seven-day-old rat pups were subjected to a modified Levine procedure, then given either vehicle or MCI-186 (at one of three dosage levels: 3, 6, or 9 mg/kg), and the extent of brain damage was evaluated either 24 h or 7 days later."( Effect of the free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), on hypoxia-ischemia-induced brain injury in neonatal rats.
Ikeda, T; Ikenoue, T; Kaneko, M; Sameshima, H; Xia, YX, 2002
)
0.31
" Based on these data in rats, dogs, and monkeys, and the established safety profile of ABT in rats dosed up to 100 mg/kg, a pretreatment at 2 h with a single oral dose of ABT at 100 mg/kg in rats (providing 93% inhibition) and 20 mg/kg in dogs and monkeys effectively inhibited the clearance of the probe compound."( Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.
Balani, SK; He, B; Lee, FW; Liu, Z; Yang, TJ; Zhu, T, 2002
)
0.55
" In this study, we evaluated the efficacy of edaravone, a newly synthesized free radical scavenger, in its clinical dosage on an experimental model of acute liver injury in rats."( A free radical scavenger, edaravone, attenuates steatosis and cell death via reducing inflammatory cytokine production in rat acute liver injury.
Ishii, H; Kameyama, K; Kitamura, K; Kurita, S; Nakamoto, N; Saito, H; Saito, Y; Tada, S, 2003
)
0.32
" The RP-HPLC method was done for the determination of paracetamol, caffeine and propyphenazone in a multicomponent pharmaceutical dosage form."( Optimization of the RP-HPLC method for multicomponent analgetic drug determination.
Ivanovic, D; Jancic, B; Malenovic, A; Medenica, M; Misljenovic, Dj, 2003
)
0.32
" The protective effect of edaravone showed the dose-response was at the same level as that of dimethylthiourea."( Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney.
Doi, K; Fujita, T; Nakao, A; Noiri, E; Suzuki, Y, 2004
)
0.32
" The results show that phenazone at a dosage of 1000 mg is effective and well tolerated in the treatment of acute migraine attacks."( Efficacy of phenazone in the treatment of acute migraine attacks: a double-blind, placebo-controlled, randomized study.
Göbel, H; Heinze, A; Niederberger, U; Witt, T; Zumbroich, V, 2004
)
0.32
" Data from the permanent MCAO model and an embolic stroke model suggested a bell shaped dose-response curve."( Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Ashwood, T; Green, AR, 2005
)
0.33
" The proposed method is rapid and sensitive and, therefore, suitable for the routine control of these ingredients in multicomponent dosage forms."( Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection.
El-Dawy, MA; Elbarbry, FA; Mabrouk, MM,
)
0.13
" Edaravone might be a hopeful therapeutic option for PD, although the high therapeutic dosage remains to be solved for the clinical application."( Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.
Agari, T; Baba, T; Date, I; Jing, M; Kameda, M; Leung, H; Matsui, T; Miyoshi, Y; Morimoto, T; Muraoka, K; Shingo, T; Tajiri, N; Uozumi, T; Wang, F; Yasuhara, T; Yuan, WJ, 2008
)
0.35
" An appropriate dosage of H(2)O(2) could hinder the occurrence of the direct photolysis."( Degradation of selected pharmaceuticals in aqueous solution with UV and UV/H(2)O(2).
Hu, C; Hu, X; Qu, J; Yang, M; Yuan, F, 2009
)
0.35
" However, the optimal total dosage of edaravone has not been established."( Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy.
Katayama, M; Shimizu, H; Unno, Y, 2010
)
0.36
"NA-3,4-DCM, dosed systemically (intraperitoneally or per os), was capable of interfering with the development of mechanical hypernociception induced by intraplantar injection of carrageenan and complete Freund adjuvant in mice."( N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.
Antonialli, CS; Corrêa, R; da Silva, GF; de Campos-Buzzi, F; Filho, VC; Quintão, NL, 2010
)
1.08
" Overall, the rate and extent of lorazepam accumulation during multiple dosage were reasonably well predicted by the single-dose kinetic study."( Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.
Allen, MD; Greenblatt, DJ; Harmatz, JS; Huffman, DH; MacLaughlin, DS; Shader, RI, 1979
)
0.26
" Method had the potential to determine these drugs simultaneously from dosage forms without any interference with each other."( Validation of an HPLC method for the simultaneous determination of diminazene diaceturate and phenazone in injectable veterinary granules and bulk powders.
Bekhit, AA; Genete, G; Hymete, A; Kassaye, L, 2012
)
0.38
" In this study, portal vein-cannulated rats were used to calculate the F(a) · F(g) of drugs from a single oral dosing experiment without data from intravenous injection."( Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats.
Kobayashi, T; Konno, Y; Matsuda, Y; Morisaki, K; Satsukawa, M; Takimoto, Y; Yamashita, S, 2012
)
0.38
" Huperzine A's permeability characteristics pave the way to the development of its oral extended release dosage form."( Transepithelial transport of a natural cholinesterase inhibitor, huperzine A, along the gastrointestinal tract: the role of ionization on absorption mechanism.
Burshtein, G; Friedman, M; Greenberg, S; Hoffman, A, 2013
)
0.39
" The potential of antipyrine phenotyping for individualisation of anesthetics' dosing is discussed."( [Phenotyping by total oxidative hepatic capacity in patients undergoing laparoscopic cholecystectomy: two categories of patients and duration of post-anesthesia rehabilitation].
Chuenkova, EA; Ziganshina, LE, 2013
)
0.72
"The aim of this study was to determine whether a tapered dosage regimen of paroxetine in pregnant women might be useful to avoid withdrawal syndromes in neonates after delivery."( Characterization of transplacental transfer of paroxetine in perfused human placenta: development of a pharmacokinetic model to evaluate tapered dosing.
Fujii, T; Hori, S; Matsuoka, S; Nagai, M; Ohtani, H; Satoh, H; Sawada, Y; Taketani, Y, 2013
)
0.39
"In a double-blind, placebo-controlled randomized clinical trial we studied two dosing regimens, each in a cohort of 18 patients."( Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Dippel, DW; Ford, GA; Kaste, M; Murayama, S; Tatlisumak, T; Walters, MR, 2013
)
0.39
" Both doses of the new formulation and dosing regimen were well tolerated."( Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Dippel, DW; Ford, GA; Kaste, M; Murayama, S; Tatlisumak, T; Walters, MR, 2013
)
0.39
"The primary objective of the present study, safety and tolerability of the new formulation and dosing regimen, was achieved."( Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Dippel, DW; Ford, GA; Kaste, M; Murayama, S; Tatlisumak, T; Walters, MR, 2013
)
0.39
" The effect of higher dosage of Edaravone on circulating MMP-9 concentration and subsequent hemorrhagic transformation should be investigated."( Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
Atsumi, C; Hagiwara, Y; Hasegawa, Y; Imai, T; Mizukami, H; Tsuruoka, A,
)
0.13
"In vivo, both Edaravone and Scutellarin markedly reduced the infarct cerebral tissue area with the latter drug being more effective with the dosage used; furthermore, when used in combination the reduction was more substantial."( Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014
)
0.4
"The results suggest that Edaravone and Scutellarin effectively suppressed the inflammatory responses in activated microglia, with Scutellarin being more efficacious within the dosage range used."( Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014
)
0.4
" We investigated the protective effects of an antioxidant substance, edaravone, and its slow-release dosage form, edaravone solid lipid nanoparticles (SLNs), in steady noise-exposed guinea pigs."( Solid lipid nanoparticles loaded with edaravone for inner ear protection after noise exposure.
Gao, G; Jiang, P; Liu, Y; Sun, JJ; Zhou, CH, 2015
)
0.42
" However, its dosage and effects have not yet been established in children."( Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone.
Aihara, Y; Kawamata, T; Nakamoto, H; Okada, Y; Yamaguchi, K, 2015
)
0.42
" Single dosed matrices are prepared by cutting the semi elastic strand with a rotary fly cutter."( Continuous production of controlled release dosage forms based on hot-melt extruded gum arabic: Formulation development, in vitro characterization and evaluation of potential application fields.
Kipping, T; Rein, H, 2016
)
0.43
" In vivo ABT administration by an osmotic pump offers an effective approach for longer-term P450 inhibition in mice and avoids the necessity for multiple dosing of the inhibitor."( Application of Osmotic Pumps for Sustained Release of 1-Aminobenzotriazole and Inhibition of Cytochrome P450 Enzymes in Mice: Model Comparison with the Hepatic P450 Reductase Null Mouse.
Ferreira, S; Ronseaux, S; Rose, J; Stringer, RA, 2016
)
0.43
" An effective dosing regimen of ABT for a multiple-administration study is needed to conduct pharmacological studies for proof-of-concept, although it has been established for single-administration study, to characterize the pharmacokinetics of drug candidates."( In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice.
Mayumi, K; Nishimura, K; Osaki, H; Watanabe, A, 2016
)
0.43
" Oral liquid dosage form is the most preferred delivery method in paediatric, geriatric and specialised therapies."( Development of a novel oral delivery system of edaravone for enhancing bioavailability.
Garg, S; Kathawala, K; Parikh, A; Tan, CC; Zhou, XF, 2016
)
0.43
"5 times the initial dosing concentration."( Osmolality of Orally Administered Solutions Influences Luminal Water Volume and Drug Absorption in Intestine.
Funai, Y; Horiuchi, T; Ichijo, K; Inoue, K; Ishihara, M; Kishimoto, H; Moteki, Y; Oda, R; Okada, R; Shirasaka, Y, 2017
)
0.46
" Questions regarding whether the dosing regimen could be simplified or improved, the duration of the effects, and the timing of the potential treatment to different stages of disease remain to be answered."( What can we learn from the edaravone development program for ALS?
Maragakis, NJ, 2017
)
0.46
"Analysis of the results of pharmacological phenotyping using antipyrine test prior to providing anesthesia for laparoscopic cholecystectomy showed that trimeperidine (promedol) dosing with allowance for the total oxidative capacity of liver and the patient mass allows the periods of post-anesthetic rehabilitation to be controlled."( POST-ANESTHETIC REHABILITATION PERIODS AND ANESTHESIA DOSAGE FOR LAPAROSCOPIC CHOLECYSTECTOMY: RELATIONSHIP TO THE TOTAL OXIDATIVE CAPACITY OF LIVER.
Chuenkova, EA; Simushkin, SV; Ziganshina, LE, 2016
)
0.68
" To investigate in vivo OATP induction, RIF (18 mg/kg per day) was orally dosed to cynomolgus monkeys for 7 days."( Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo.
Lai, Y; Murakami, E; Niu, C; Smith, B; Subramanian, R; Tep, S; Wang, Y; Zhao, X, 2019
)
0.51
"5-HT-excessive rats were prepared by multiple intraperitoneal dosing of 5-HT and clorgyline, an inhibitor for 5-HT metabolism, and utilized to examine the pharmacokinetics, absorption behavior and the intestinal permeability for CEX."( Effect of Excessive Serotonin on Pharmacokinetics of Cephalexin after Oral Administration: Studies with Serotonin-Excessive Model Rats.
Higaki, K; Iwamoto, T; Maruyama, M; Nakashima, S; Ogawara, KI; Takanashi, M, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
cyclooxygenase 3 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 3.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrazoloneA member of the class of pyrazoles in which one of the carbons of the pyrazole ring is substituted by an oxo group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Antipyrine Action Pathway2967

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
GLI family zinc finger 3Homo sapiens (human)Potency55.92640.000714.592883.7951AID1259369
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency7.49780.001022.650876.6163AID1224838
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.11220.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency49.84440.003041.611522,387.1992AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.87240.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency35.60910.000229.305416,493.5996AID743069
67.9K proteinVaccinia virusPotency2.56200.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency25.11890.001024.504861.6448AID588535
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00630.010039.53711,122.0200AID588545
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.43790.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency0.23110.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)422.66670.11007.190310.0000AID1443980; AID1449628; AID1473738
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00100.00000.00060.0019AID1618606
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (232)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID24180Permeability coefficient reported; (Expressed as Permeability coefficient x 10 e 4 cm/s)1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID266763Membrane retention in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID266767Membrane retention in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID604579Metabolic stability in rat liver microsomes assessed as norantipyrine formation per mg of protein after 20 mins by HPLC analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1134606Et2O-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1221016Intrinsic elimination clearance in healthy Wistar rat perfused liver assessed per gm of liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID15711Calculated partition coefficient (clogP)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID29845Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1220980Dissociation constant, pKa of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1134605Oil-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID18861GOF value represents multisets of log P data1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1221012Apparent distribution ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID27575HPLC capacity factor (k)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID604582Drug excretion in rat urine assessed as norantipyrine formation at 100 mg/kg, po measured after 24 hrs by HPLC analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1221000Permeability surface area product in healthy Wistar rat perfused liver assessed per gm of liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1220988Extraction ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID266762Effective permeability coefficient in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID604581Drug excretion in rat urine assessed as hydroxymethylpyrine formation at 100 mg/kg, po measured after 24 hrs by HPLC analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1220984Extraction ratio of the compound in healthy Wistar rat perfused liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID24185Distribution coefficient in octanol/water at pH 7.41998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID266765Effective permeability coefficient in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID26380Dissociation constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1220979Octanol-water apparent partition coefficient, logD of the compound at pH 7.42011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1145613Drug absorption in rat small intestine1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID21849In vitro clearance in dog in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID604524Antigenicity in guinea pig assessed as erythema in abdomen at 1 mg/kg, id measured after 24 hrs by skin reaction assay2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID21858In vivo clearance in rat1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1294650Permeability of the compound at 50 uM at pH 7.4 after 4 hrs by PAMPA-GIT assay2016European journal of medicinal chemistry, May-23, Volume: 114Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment.
AID1145608Drug absorption in anesthetized rat colon at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1220992Mean transit time of the compound in healthy Wistar rat perfused liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID604584Drug excretion in rat urine at 100 mg/kg, po measured after 24 hrs by HPLC analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID303929Permeability across artificial membrane by PAMPA model2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID28957Partition coefficient (logP)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID681118TP_TRANSPORTER: transepithelial transport in Caco-2 cells2003International journal of pharmaceutics, Sep-16, Volume: 263, Issue:1-2
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID604523Antinociceptive activity in rat assessed as suppression of carrageenan-induced nociception in right hind paw at 100 mg/kg, po measured after 1 hr2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1221008Apparent distribution ratio of the compound in healthy Wistar rat perfused liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID266769Membrane retention in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID604583Drug excretion in rat urine assessed as hydroxyantipyrine formation at 100 mg/kg, po measured after 24 hrs by HPLC analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID21264Effective permeability measured in human.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID27580Partition coefficient (logP)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID604578Metabolic stability in rat liver microsomes assessed as hydroxymethylpyrine formation per mg of protein after 20 mins by HPLC analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID266766Dissociation constant, pKa of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID156202Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1211792Hepatic clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID604580Metabolic stability in rat liver microsomes assessed as hydroxyantipyrine formation per mg of protein after 20 mins by HPLC analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID21851In vitro clearance in human in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID29344Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID266764Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1169140Retention time of the compound by EPSA supercritical fluid chromatography2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1145610Dissociation constant, pKa of the compound at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID156204Binding to POPC/GMI liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID266770Membrane permeability, CA(t)/CD(0) in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1221020Intrinsic elimination clearance in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID23734Micelle/water partition coefficient (Pmic) of the compound was determined1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1145612Dissociation constant, pKa of the compound at pH 5.31977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID28958Partition coefficient across water-dodecane interface by statistical simulation2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID237585Tested for fraction of oral dose absorbed orally in humans2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID266771Permeability in human skin2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1220996Mean transit time of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1211798Intrinsic clearance in human using well stirred liver model by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID15120Percent of the drug absorbed after administration to humans was determined1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
AID1221004Permeability surface area product in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 4 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID24183Distribution coefficient in octanol/water at pH 5.51998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID24184Distribution coefficient in octanol/water at pH 6.51998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID18847Percent of drug absorbed by human intestine after oral administration2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
AID28956Partition coefficient (logP) (dodecane)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1211797Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID21853In vivo clearance in dog1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1211795Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1211794Fraction unbound in blood (not specified)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID236913Permeability Coefficient in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID1145606Octanol-aqueous phase partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID24420Partition coefficient (logP)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID604525Metabolic stability in rat liver microsomes assessed as increase in D-methylation products after 20 mins by HPLC analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID266768Membrane permeability, CA(t)/CD(0) in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID29421Partition coefficient (logP) (HPLC)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID236916Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID681792TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Antipyrine: 1000 uM) in Xenopus laevis oocytes1999Molecular pharmacology, May, Volume: 55, Issue:5
Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID21852In vitro clearance in rat in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1764875Permeability of the compound at 50 uM measured after 4 hrs by PAMPA assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Discovery of novel potent migrastatic Thiazolo[5,4-b]pyridines targeting Lysyl-tRNA synthetase (KRS) for treatment of Cancer metastasis.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID303797Permeability across artificial membrane by PAMPA2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Multiple N-methylation by a designed approach enhances receptor selectivity.
AID26400pKa value of the compound. (extrapolated value)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID310932Permeability across human Skin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID604519Antipyretic activity against IL-1beta-induced hyperthermia in rat assessed as change in rectal temperature at 100 mg/kg, icv measured after 2 hrs2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics.
AID21856In vivo clearance in human1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1211791Fraction unbound in human hepatocytes2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,255)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902381 (55.96)18.7374
1990's665 (15.63)18.2507
2000's601 (14.12)29.6817
2010's564 (13.25)24.3611
2020's44 (1.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.81 (24.57)
Research Supply Index8.49 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index113.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (63.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials241 (5.22%)5.53%
Reviews175 (3.79%)6.00%
Case Studies80 (1.73%)4.05%
Observational3 (0.06%)0.25%
Other4,122 (89.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Assessing the Efficacy of Antipyrine Benzocaine Otic Solution in the Ear Canal to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults. [NCT02153541]Phase 250 participants (Anticipated)Interventional2023-04-01Not yet recruiting
A Four-arm, Randomized, Double-blind, Active and Placebo Controlled Study to Determine the Safety and Efficacy of a Combination Antipyrine and Benzocaine Otic Solution Compared With Antipyrine Otic Solution Alone, Benzocaine Otic Solution Alone and to Pla [NCT02037893]Phase 2112 participants (Actual)Interventional2013-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R)
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 12 Hours Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 24 Hours Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 3 Hour Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 30 Min Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 36 Hours Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 48 Hours Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 6 Hours Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 60 Hours Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 72 Hours Post First Dose
NCT02037893 (11) [back to overview]Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R)15 Min Post First Dose

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R)

"The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Baseline and 1 hour after a single dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-4.3
Antipyrine Otic Solution-5.0
Benzocaine Otic Solution-4.6
Placebo-4.9

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 12 Hours Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 12 hour post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-3.9
Antipyrine Otic Solution-4.3
Benzocaine Otic Solution-4.1
Placebo-4.0

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 24 Hours Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 24 hour post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-5.5
Antipyrine Otic Solution-4.4
Benzocaine Otic Solution-4.2
Placebo-4.6

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 3 Hour Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 3 hour post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-3.4
Antipyrine Otic Solution-3.9
Benzocaine Otic Solution-3.8
Placebo-3.5

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 30 Min Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 30 min post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-3.9
Antipyrine Otic Solution-4.3
Benzocaine Otic Solution-4.4
Placebo-4.8

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 36 Hours Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 36 hour post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-5.5
Antipyrine Otic Solution-4.6
Benzocaine Otic Solution-4.4
Placebo-5.5

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 48 Hours Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 48 hour post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-5.4
Antipyrine Otic Solution-5.3
Benzocaine Otic Solution-4.7
Placebo-5.9

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 6 Hours Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 6 hour post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-3.4
Antipyrine Otic Solution-4.0
Benzocaine Otic Solution-3.9
Placebo-3.8

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 60 Hours Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 60 hour post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-5.4
Antipyrine Otic Solution-5.4
Benzocaine Otic Solution-5.4
Placebo-6.2

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) 72 Hours Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 72 hour post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-5.9
Antipyrine Otic Solution-5.9
Benzocaine Otic Solution-5.4
Placebo-6.1

[back to top]

Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R)15 Min Post First Dose

"The relative change from baseline in pain intensity as measured by changes in FLACC scores or FPS-R scores between baseline and 15 and 30 minutes, and 3, 6, 12, 24, 36, 48, 60, and 72 hours after first dose.~The FLACC was completed by the caregiver to assess pain intensity for subjects aged 2 months to less than 5 years. The FLACC consists of five domains that are rated as 0, 1, or 2 (total scores range from 0 to 10). A lower score indicates lower level of pain.~The FPS-R was completed by the subject aged 5 to 12 years. For this assessment, the subject selected the pain intensity by using faces that show increasing discomfort. Total scores range from 0 to 10. A lower score indicates lower level of pain." (NCT02037893)
Timeframe: Change from Baseline to 15 min post first dose

Interventionunits on a scale (Mean)
Antipyrine and Benzocaine Otic Solution-3.6
Antipyrine Otic Solution-3.6
Benzocaine Otic Solution-3.4
Placebo-3.8

[back to top]